WEST Search History

DATE: Wednesday, November 26, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=AND		
L1	map near2 kinase	1242	L1
L2	L1 same (dual or double or multiple or two or 2) same (phosphor$ or phosphat$)	444	L2
L3	L2 same (substrate or peptide or polypeptide or poly-peptide or protein or amino or epitope)	397	L3
L4	L3 same (method or assay or assaying or detect or determine or detecting or evaluating or identifying or identified or test or testing or screening or screen or evaluation)	179	L4
L5	l4 same (monoclonal or antibody or antibodies or antisera or antiserum or mono-clonal or moab or mab or scfv or antipeptide or antisubstrate)	31	L5

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 31 of 31 returned.

☐ 1. Document ID: US 6649391 B1

L5: Entry 1 of 31 File: USPT Nov 18, 2003

DOCUMENT-IDENTIFIER: US 6649391 B1
TITLE: DSP-11 dual-specificity phosphatase

Detailed Description Text (37):
For example, [.sup.32 P]-radiolabeled substrate (e.g., MAP-kinase) may be used for the kinase reaction, resulting in radiolabeled, activated MAP-kinase. A DSP-11 polypeptide may then be tested for the ability to dephosphorylate an activated MAP-kinase by contacting the DSP-11 polypeptide with the MAP-kinase under suitable conditions (e.g., Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mg/mL bovine serum albumin for 10 minutes at 30.degree. C.; or as described by Zheng and Guan, J. Biol. Chem. 268:16116-16119, 1993). Dephosphorylation of the MAP-kinase may be detected using any of a variety of assays, such as a coupled kinase assay (evaluating phosphorylation of a MAP-kinase substrate using any assay generally known in the art) or directly, based on (1) the loss of radioactive phosphate groups (e.g., by gel electrophoresis, followed by autoradiography); (2) the shift in electrophoretic mobility following dephosphorylation; (3) the loss of reactivity with an antibody specific for phosphotyrosine or phosphothreonine; or (4) a phosphoamino acid analysis of the MAP-kinase. Certain assays may generally be performed as described by Ward et al., Nature 367:651-654, 1994 or Alessi et al., Oncogene 8:2015-2020, 1993. In general, contact of 500 pg-50 ng of DSP-11 polypeptide with 100 ng-100 .mu.g activated MAP-kinase should result in a detectable dephosphorylation of the MAP-kinase, typically within 20-30 minutes. Within certain embodiments, 0.01-10 units/mL (preferably about 0.1 units/mL, where a unit is an amount sufficient to dephosphorylate 1 nmol substrate per minute) DSP-11 polypeptide may be contacted with 0.1-10 .mu.M (preferably about 1 .mu.M) activated MAP-kinase to produce a detectable dephosphorylation of a MAP-kinase. Preferably, a DSP-11 polypeptide results in a dephosphorylation of a MAP-kinase or a phosphorylated substrate (such as a tyrosine-and/or serine-phosphorylated peptide) that is at least as great as the dephosphorylation observed in the presence of a comparable amount of native human DSP-11. It will be apparent that other substrates identified using a substrate trapping mutant as described herein may be substituted for the MAP-kinase within such assays.

Detailed Description Text (78):
In one aspect of the present invention, DSP-11 polypeptides may be used to identify agents that modulate DSP-11 activity. Such agents may inhibit or enhance signal transduction via a MAP-kinase cascade, leading to cell proliferation. An agent that modulates DSP-11 activity may alter expression and/or stability of DSP-11, DSP-11 protein activity and/or the ability of DSP-11 to dephosphorylate a substrate. Agents that may be screened within such assays include, but are not limited to, antibodies and antigen-binding fragments thereof,

competing substrates or peptides that represent, for example, a catalytic site or a dual phosphorylation motif, antisense polynucleotides and ribozymes that interfere with transcription and/or translation of DSP-11 and other natural and synthetic molecules, for example small molecule inhibitors, that bind to and inactivate DSP-11.

☐ 2. Document ID: US 6645753 B1

L5: Entry 2 of 31 File: USPT Nov 11, 2003

DOCUMENT-IDENTIFIER: US 6645753 B1
TITLE: DSP-5 dual-specificity phosphatase

Detailed Description Text (39):
For example, [.sup.32 P]-radiolabeled substrate (e.g., MAP-kinase) may be used for the kinase reaction, resulting in radiolabeled, activated MAP-kinase. A DSP-5 (or DSP-5 alternate form) polypeptide may then be tested for the ability to dephosphorylate an activated MAP-kinase by contacting the DSP-5 polypeptide with the MAP-kinase under suitable conditions (e.g., Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mg/mL bovine serum albumin for 10 minutes at 30.degree. C.; or as described by Zheng and Guan, J. Biol. Chem. 268:16116-16119, 1993). Dephosphorylation of the MAP-kinase may be detected using any of a variety of assays, such as a coupled kinase assay (evaluating phosphorylation of a MAP-kinase substrate using any assay generally known in the art) or directly, based on (1) the loss of radioactive phosphate groups (e.g., by gel electrophoresis, followed by autoradiography); (2) the shift in electrophoretic mobility following dephosphorylation; (3) the loss of reactivity with an antibody specific for phosphotyrosine or phosphothreonine; or (4) a phosphoamino acid analysis of the MAP-kinase. Certain assays may generally be performed as described by Ward et al., Nature 367:651-654, 1994 or Alessi et al., Oncogene 8:2015-2020, 1993. In general, contact of 500 pg--50 ng of DSP-5 polypeptide with 100 ng-100 .mu.g activated MAP-kinase should result in a detectable dephosphorylation of the MAP-kinase, typically within 20-30 minutes. Within certain embodiments, 0.01-10 units/mL (preferably about 0.1 units/mL, where a unit is an amount sufficient to dephosphorylate 1 nmol substrate per minute) DSP-5 polypeptide may be contacted with 0.1-10 .mu.M (preferably about 1 .mu.M) activated MAP-kinase to produce a detectable dephosphorylation of a MAP-kinase. Preferably, a DSP-5 polypeptide results in a dephosphorylation of a MAP-kinase or a phosphorylated substrate (such as a tyrosine- and/or serine-phosphorylated peptide) that is at least as great as the dephosphorylation observed in the presence of a comparable amount of native human DSP-5 (or DSP-5 alternate form). It will be apparent that other substrates identified using a substrate trapping mutant as described herein may be substituted for the MAP-kinase within such assays.

Detailed Description Text (81):
In one aspect of the present invention, DSP-5 (or DSP-5 alternate form) polypeptides may be used to identify agents that modulate DSP-5 activity. Such agents may inhibit or enhance signal transduction via a MAP-kinase cascade, leading to cell proliferation. An agent that modulates DSP-5 (or DSP-5 alternate form) activity may alter expression and/or stability of DSP-5, DSP-5 protein activity and/or the ability of DSP-5 to

dephosphorylate a substrate. Agents that may be screened within such assays include, but are not limited to, antibodies and antigen-binding fragments thereof, competing substrates or peptides that represent, for example, a catalytic site or a dual phosphorylation motif, antisense polynucleotides and ribozymes that interfere with transcription and/or translation of DSP-5 (or DSP-5 alternate form) and other natural and synthetic molecules, for example small molecule inhibitors, that bind to and inactivate DSP-5 (or DSP-5 alternate form).

☐ 3. Document ID: US 6632628 B1

L5: Entry 3 of 31 File: USPT Oct 14, 2003

DOCUMENT-IDENTIFIER: US 6632628 B1
TITLE: Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression

Detailed Description Text (270):
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. U.S. Pat. No. 5,359,046 U.S. Pat. No. 4,367,110 U.S. Pat. No. 4,452,901 U.S. Pat. No. 4,668,621 U.S. Pat. No. 4,873,191 U.S. Pat. No. 5 ,708,158 U.S. Pat. No. 5,252,479 U.S. Pat. No. 5,672,344 WO 84/03564 Adolph et al., "Role of myocyte-specific enhancer-binder factor (MEF-2) in transcriptional regulation of the acardiac myosin heavy chain gene," J. Biol. Chem., 268:5349-5352, 1993. Baichwal and Sugden, In: Gene Transfer, Kucherlapati R, ed., New York, Plenum Press, 117-148, 1986. Batterson and Roizman, J. Virol., 46:371-377, 1983. Bedzyk et al., J. Biol. Chem., 265:18615, 1990. Bellon et al., de Ses Filiales, 190(1):109-142, 1996. Benvenisty and Neshif, Proc. Nat'l Acad. Sci. USA, 83:9551-9555, 1986. Berns and Bohenzky, Adv. Virus Res., 32:243-307, 1987. Berns and Giraud, Curr. Top. Microbiol. Immunol., 218:1-23, 1996. Berns, Microbiol Rev., 54:316-329, 1990. Bertran et al., J. Virol., 70(10):6759-6766, 1996. Bito et al., "CREB Phosphorylation and Dephosphorylation: Aca2+- and Stimulus Duration-Dependent Switch for Hippocampal Gene Expression," Cell,. 87:1203-1214, 1996. Botinelli et a., Circ. Res. 82:106-115, 1997. Bour et al., "Drosophila MEF2, a transcription factor that is essential for myogenesis," Genes and Dev., 9:730-741, 1995. Bowman et al., "Expression of Protein Kinase C B in the Heart Causes Hypertrophy in Adult Mice and Sudden Death in Neonates," J. Clin. Invest., 100:2189-2195, 1997. Brand, "Myocyte enhancer factor 2 (MEF2)," Int J. Biochem. Cell Biol., 29:1467-1470; 1997. Brinster et al., Proc. Nat'l Acad. Sci. USA, 82: 4438-4442, 1985. Brown et al., J. Neurochem. 40:299-308, 1983. Bustamante et al., J. Cardiovasc. Pharmacol, 17: S110-113, 1991. Chaudhary et al., Proc. Nat'l Acad. Sci., 87:9491, 1990. Chen and Okayama, Mol. Cell Biol., 7:2745-2752, 1987. Chien et al., Ann. Rev. Physiol. 55, 77-95, 1993. Chien et al., "Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response," FASEB J., 5:3037-3046, 1991. Chomczynski and Sacchi, Anal. Biochem., 162:156-159, 1987. Clarke et al., "Epidermal Growth Factor Induction of the c-jun Promoter by a Rac Pathway," Mol. Cell Biol., 18:1065-1073, 1998. Coffin, In., Fields BN, Knipe DM, ed. VIROLOGY. New York: Raven Press, pp. 1437-1500, 1990. Colbert et al., "Cardiac Compartment-specific Overexpression of a Modified Retinoic Acid Receptor Produces Dilated Cardiomyopathy and Congestive Heart Failure in Transgenic Mice," J. Clin. Invest., 100: 1958-1968, 1997. Coso et al., "Signaling from G Protein-coupled Receptors to the c-jun promoter

Involves the MEF2 Transcription Factor," J. Biol. Chem., 272:20691-20697, 1997. Couch et al., Am. Rev. Resp. Dis., 88:394-403, 1963. DeLuca et al., J. Virol., 56:558-570, 1985. Dolmetsch et al., "Differential activation of transcription factors induced by Ca.sup.2+ response amplitude and duration," Nature, 386:855-858, 1997. Dubensky et al, Proc. Nat'l Acad. Sci. USA, 81:7529-7533, 1984. Edmondson et al., "MEF2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis," Development, 120:1251-1263, 1994. Ellis et al., "Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity," 1986. Elroy-Stein et al., Proc. Nat'l Acad. Sci. USA, 1989. Elshami et al., Gene Therapy, 7(2):141-148, 1996. Emmel et al., "Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation," Science, 246:1617-1620, 1989. Evans, "Regulation of Cardiac Gene Expression by GATA-4/5/6," Trends in Cardiovascular Medicine, 7:75-83, 1997. Fechheimer et al., Proc. Nat'l. Acad. Sci. USA, 84:8463-8467, 1987. Feldman et al., "Selective Gene Expression in Failing Human Heart," Circulation, 83:1866-1872, 1991. Ferkol et al., FASEB J., 7:1081-1091, 1993. Fischele et al., J. Biol. Chem., 274:11713-11720, 1999. Flanagan et al., "Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A," Nature, 352:803-807, 1991. Fraley et al., Proc. Nat'l Acad. Sci. USA, 76:3348-3352, 1979. French et al., Circulation, 90(5):2414-2424, 1994. Freshner, In Animal Cell Culture: a Practical Approach Second Edition, Oxford/New York, IRL Press, Oxford University Press, 1992. Ghosh-Choudhury et al., EMBO J., 6:1733-1739, 1987. Ghosh and Bachhawat, (Wu G, Wu C ed.), New York: Marcel Dekker, pp. 87-104, 1991. Ginsberg et al., Proc. Nat'l Acad. of Sci. USA, 88(5)1651-1655, 1991. Glorioso et al., Ann. Rev. Microbiol. 49:675-710, 1995. Gomez-Foix et al., J. Biol. Chem., 267:25129-25134, 1992. Gopal, Mol. Cell Biol., 5:1188-1190, 1985. Gossen and Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," Proc. Nat'l Acad. Sci., 89:5547-5551, 1992. Gossen et al., Science, 268:1766-1769, 1995. Graham and Prevec, Biotechnology, 20:363-390, 1992. Graham and Prevec, In: E. J. Murray (ed.), Methods in Molecular Biology: Gene Transfer and Expression Protocol, Clifton, N.J.: Humana Press, 7:109-128, 1991. Graham and Van Der Eb, Virology, 52:456-467, 1973. Graham et al., J. Gen. Virol., 36:59-72, 1977. Grepin et al., Mol. Cell. Biol., 14:3115-3129, 1994. Grozinger et al., Proc. Nat'l. Acad. Sci., 96:4868-4873, 1999. Grunhaus and Horwitz, Seminar in Virology, 3:237-252, 1992. Gruver et al., "Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice," Endocrinology, 133:376-388, 1993. Han et al., "Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation," Nature, 386:296-299, 1997. Harland and Weintraub, J. Cell Biol., 101:1094-1099, 1985. Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y., 1988. Hasegawa et al., "Cis-acting sequences that mediate induction of the -myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction," Circulation, 96:3943-3953, 1997. Haverich et al., Transplant Proc., 26:2713-2715, 1994. Hersdorffer et al., DNA Cell Biol., 9:713-723, 1990. Herz and Gerard, Proc. Nat'l Acad. Sci. USA, 90:2812-2816, 1993. Herzig et al., "Angiotensin II type 1a receptor gene expression in the heart: AP-1 and GATA-4 mediate the response to pressure overload," Proc. Nat'l Acad. Sci. USA, 94:7543-7548, 1997. Ho et al., J. Biol. Chem., 270:19898-19907, 1995. Ho et al., "Activation of protein I-dependent transcriptional activation of interleukin 2 gene by Ca.sup.++ /calmodulin kinase type IV/Gr," J. Exp. Med., 184:101-112, 1996. Hoey et al., "Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins," Immunity, 2:461-472, 1995. Hogan et al., "Manipulating the Mouse Embryo" Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986. Holland et al., Virology, 101:10-18, 1980. Honess and Roizman, J. Virol., 14:8-19, 1974. Honess and Roizman, J. Virol., 16:1308-1326, 1975. Hongo et al., Am. J. Physiol., 269: C690-C697, 1995. James and Olson, "Deletion of the regulatory domain of protein kinase C exposes regions in the hinge and catalytic domains that mediate nuclear targeting," J. Cell Biol., 116:863-874, 1992. Johnson et al., BIOTECHNOLOGYAND PHARMACY, Pezzuto et al., eds., Chapman and Hall, New York, 1993. Jones and Shenk, Cell, 13:181-188, 1.978. Jones et al., J. Clin. Invest., 98:1906-1917, 1996. Jones, Sanchez, Robbins, "Murine pulmonary myocardium: developmental analysis of cardiac gene expression," Dev. Dyn., 200:117-128, 1994. Kaneda et al., Science, 243:375-378, 1989. Kao et al., "Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression," Genes Dev., 14(1):55-66, 2000. Kariya et al., "An enhancer core element mediates stimulation of the rat-myosin heavy chain promoter by an .sub.1 -adrenergic agonist and activated -protein

kinas C in hypertrophy of cardiac myocytes," J. Biol. Chem., 269:3775-3782, 1994. Karliner et al., "Effects of pertussis toxin on 1-agonist-mediated phosphatidylinositide turnover anh myocardial cell hypertrophy in neonatal rat myocytes," Experientia., 46:81-84, 1990. Karlsson et al., EMBO J., 5:2377-2385, 1986. Karns et al., "M-CAT, CarG, and Sp1 elements are required for)-adrenergic induction of the skeletal -actin promoter during cardiac myocyte hypertrophy," J. Biol. Chem., 270:410-417, 1995. Kato et al., J. Biol. Chem., 266:3361-3364, 1991. Kato et al., "BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C," EMBO J., 16:054-066, 1997. Kearns et al., Gene Ther., 3:748-755, 1996. Kincaid et al., "Cloning and characterization of molecular isoforms of the catalytic subunit of calcineurin using nonisotopic methods," J. Biol. Chem., 265:11312-11319, 1990. Klein et al., Nature, 327:70-73, 1987. Komuro and Yazaky, "Control of cardiac gene expression of mechanical stress," Annu. Rev. Physiol., 55:55-75, 1993. Kotin and Berns, Virol., 170:460-467, 1989. Kotin et al., Genomics, 10:831-834, 1991. Kotin et al., Proc. Nat'l Acad. Sci. USA, 87:2211-2215, 1990. Kovacic-Milivojevic et al., Endocrin, 137:1108-1117, 1996. Kovacic-Milivojevic et al., "Selective regulation of the atrial natriuretic peptide gene by individual components of the activator protein-I complex," Endocrinology, 137:1008-1117, 1996. Kudoh et al., Circ. Res., 80:139-146, 1997. LaPointe et al., Hypertension, 27:715-722, 1996. Le Gal La Salle et al., Science, 259:988-990, 1993. Le Guennec et al., Exp. Physiol., 6:975-978, 1991. Lee et al., "Myocyte-Specific Enhancer Factor 2 and Thyroid Hormone Receptor Associate and Synergistically Activate the .alpha.-Cardiac Myosin Heavy-Chain Gene," Mol. Cell Biol., 17:2745-2755, 1997. Leite et al., "Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: desensitization and receptor subtype," Am. J. Physiol., 267:H2193-2203, 1994. Levrero et al., Gene, 101:195-202, 1991. Li et al., "FGF inactivates myogenic helix- loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA binding domains," Cell, 71:1181-1194, 1992. Lilly et al., "Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila," Science, 267:688-693, 1995. Lin et al, J. Clin. Invest., 97:2842-2848, 1996. Lin et al., "Control of cardiac morphogenesis and myogenesis by the myogenic transcription factor MEF2C," Science, 276:1404-1407, 1997. Liu et al., "Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member," EMBO J., 16:143-153, 1997. Loh et al., J. Biol. Chem., 271:10884-10891, 1996b. Loh et al., Mol. Cell. Biol., 16:3945-3954, 1996a. Lyakh et al., Mol. Cell Biol., 17:2475-2482, 1997. Mann et al., Cell, 33:153-159, 1983. Marban et al., Proc. Nat'l Acad. Sci. USA, 84:6005-6009, 1987. Markowitz et al., J. Virol., 62:1120-1124, 1988. Martin et al., "Myocyte enhancer factor (MEF) 2C: A tissue-restricted member of the MEF-2 family of transcription factors," Proc. Nat'l Acad. Sci. USA, 90:5282-5286, 1993. Masuda et al., Mol. Cell. Biol., 15:2697-2706, 1995. Masuda et al., "NF-ATx, a novel member of the nuclear factor of activated T cells family that is expressed predominately in the thymus," Mol. Cell. Biol., 15:2697-2706, 1995. McCaffery et al., Science, 262:750-754, 1993. Mercadier et al., "Altered sarcoplasmic reticulum Ca.sup.++ -ATPase gene expression in the human ventricle during end-stage heart failure," J. Clin. Invest., 85:305-309, 1995. Mizukami et al., Virology, 217:124-130, 1996. Molkentin and Olson, "Combinational Control of Muscle Development by bHLH and MADS-box Transcription Factors," Proc. Nat'l Acad. Sci. USA, 93:9366-9373, 1996. Molkentin and Olson, Circulation, 96:3833-3835, 1997. Molkentin et al., Mol. Cell Biol., 16:2627-2536, 1996. Molkentin et al., Mol. Cell. Biol., 14:4947-4957, 1994. Molkentin, et al., "Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins," Cell, 83:1125-1136, 1995. Molkentin et al., "Mutational analysis of the DNA binding, dimerization, and transcriptional activation of MEF2C," Mol. Cell. Biol., 16:2627-2636, 1996a. Molkentin et al., "MEF2B is a potent transactivator expressed in early myogenic lineages," Mol. Cell. Biol., 16:3814-3824, 1996b. Molkentin et al., "Phosphorylation of the MADS-box transcription factor MEF2C enhances its DNA binding activity," J. Biol. Chem., 271:17199-17204, 1996c. Molkentin et al., "Requirement of the GATA4 Transcription factor for heart tube formation and ventral morphogenesis," Genes and Dev., 11: 1061-1072, 1997. Morgan et al., Annu. Rev. Physiol., 49:533-543, 1987. Mulligan, Science, 260:926-932, 1993. Myers, EPO 0273085. Nicolas and Rubenstein, In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt (eds.), Stoneham: Butterworth, pp. 494-513, 1988. Nicolau and Sene, Biochem.

☐ 4. Document ID: US 6613956 B1

L5: Entry 4 of 31 File: USPT Sep 2, 2003

DOCUMENT-IDENTIFIER: US 6613956 B1
TITLE: PI 3-kinase fusion mutants and uses thereof

Detailed Description Text (106):
Cell lysates containing HA-tagged pp70 S6 kinase, Akt-kinase, MAP-kinase or cJun terminal kinase (JNK) were incubated with monoclonal anti-HA antibody 12CA5 for 1 hour at 4.degree. C. Protein A-Sepharose beads (Sigma, St. Louis, Mo.) were used to precipitate the immune complexes. The beads were washed with 50 mM Tris-HCl (pH 7.5), 0.5 M LiCl, 0.5% v/v Triton X-100, twice with PBS and once with 10 mM Tris-HCl (pH 7.5), 10 mM MgCl.sub.2, 1 mM dithiothreitol, all containing 0.1 mM sodium vanadate and 20 mM .beta.-glycerolphosphate. For analyzing the immune complexes in an S6 kinase activity assay the beads were divided in three aliquots: two aliquots were subjected to a S6 kinase activity assay using [.lambda.-.sup.32 p] ATP (5,000 Ci/mmol) based on a peptide substrate described in Terada et al, J. Biol. Chem. 268: 12062-8 (1993), in 30 .mu.l, one aliquot was analyzed for the amount of recombinant pp70 S6 kinase in the precipitate. After 25 minutes at 22.degree. C. the reaction was stopped by the addition of 10 .mu.l of 500 mM EDTA. Twenty two .mu.l of the supernatant was applied to phosphocellulose paper P81 made by Whatman Products, Fisher Scientific, Pittsburg, Pa., and washed four times in 75 mM H.sub.3 PO.sub.4. The relative amounts of incorporated radioactivity was determined in a liquid scintillation counter. Specific phosphorylation of the S6-derived peptide was obtained after subtracting counts with protein A-Sepharose beads in the absence of anti-HA-antibody from counts of label incorporated in the presence of anti-HA-antibody.

Detailed Description Text (107):
For all the other kinase assays, one-third of the immunobeads were subjected to an in vitro kinase reaction, and two-thirds were analyzed for the amount of the respective recombinant kinase protein. For analyzing Akt kinase activity histone H2B was used as substrate as described in Franke et al., Cell 81:727-36 (1995), according to the reaction conditions described by Jones et al, PNAS USA 88:4171-5 (1991). JNK-activity was determined using GST-Jun (amino acids of Jun 1 through 89, which a slight variation from a standard version that contains amino acids 1 through 79) as a substrate as described in Derijard et al., Cell 76:1025-37 (1994). For MAP kinase activation, the phosphorylation of myelin basic protein (MBP) was analyzed as described by Ray et al., PNAS USA 85:3753-7 (1988). The in vitro protein kinase reactions were carried out in 30 .mu.l in the presence of [y-.sup.32 p] ATP (5,000 Ci/mmol) and incubated at 22.degree. C. for 25 minutes. The reactions were stopped by the addition of 8 .mu.l Lammli-sample buffer and 22 .mu.l of the reaction mixtures were analyzed by SDS-PAGE. The relative amounts of incorporated radioactivity was determined by autoradiography and quantitated using a Molecular Imager System produced by BioRad, Richmond, Calif. The complexes were analyzed by immunoblotting with the indicated antibodies.

☐ 5. Document ID: US 6610523 B1

L5: Entry 5 of 31 File: USPT Aug 26, 2003

DOCUMENT-IDENTIFIER: US 6610523 B1
TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Detailed Description Text (144):
To examine the specificity of MKK7 in vivo, cotransfection assays were performed. CHO cells were maintained in Dulbecco's modified Eagle's medium supplemented with fetal calf serum (5%; Gibco-BRL). The cells were transfected with the lipofectamine reagent according to the manufacturer's recommendations (Gibco-BRL)(Derijard (1994) supra). Cells were co-transfected with vectors encoding epitope-tagged JNK1 together with an empty expression vector (control) or an expression vector encoding MKK4 or MKK7. The epitope tag was derived from the hemagglutinin protein (HA) of the influenza virus. JNK1 was isolated by immunoprecipitation of cell lysates. The cells were solubilized with lysis buffer (20 mM Tris (pH 7.4), 1% TRITON X-100.RTM., 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM .beta.-glycerophosphate, 1 mM Na orthovanadate, 2 mM pyrophosphate, 1 mM PMSF, 10 .mu.g/ml leupeptin) and centrifuged at 100,000.times.g for 15 minutes at 4.degree. C. The epitope-tagged protein kinases were immunoprecipitated by incubation for 3 hours at 4.degree. C. with an anti-HA monoclonal antibody bound to protein-G Sepharose (Pharmacia-LKB Biotechnology Inc.). The immunoprecipitates were washed three times with lysis buffer (Gupta et al. (1995) Science 267:389-393). Protein kinase activity was measured in the immunecomplex with [.gamma.-.sup.32 P]ATP and c-Jun as substrates. The product of the phosphorylation reaction was visualized after SDS-PAGE by autoradiography. The ERK2 and p38 MAP kinases were not activated by co-expressed MKK7. Control experiments demonstrated that the ERK2 and p38 MAP kinases were activated by their respective cognate MAP kinase kinases, MKK1 and MKK6. In contrast, MKK7 did activate JNK1. Interestingly, the activation of JNK1 by co-expressed MKK7 was greater than that caused by the previously described JNK activator MKK4. Together, these data establish that MKK7 can function as a specific activator of JNK in cultured cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 6. Document ID: US 6586191 B2

L5: Entry 6 of 31 File: USPT Jul 1, 2003

DOCUMENT-IDENTIFIER: US 6586191 B2
TITLE: Method of identifying compounds that bind galanin receptor (GALR2)

Detailed Description Text (233):
CHO cells expressing either the rat GALR2 receptor or the human GALR2 receptor were plated at .about.50%

confluence into well-plates and grown in culture with fetal bovine serum reduced to 0.5% for 2 days. Fresh medium was exchanged for old and then aspirated after 2 hrs. The assay was initiated by adding fresh medium plus or minus 1 uM human galanin for 10 minutes. Cells were washed with phosphate buffered saline and lysed in 100 uL Laemmli sample buffer (Bio-Rad) containing 5% .beta.-mercaptoethanol. Cell lysate was scraped off the plate, transferred to a microfuge tube on ice, and sonicated for 10-15 seconds. Samples were heated at 100.degree. C. for 3-5 minutes. Insoluble material was collected by centrifugation at 10,000.times.g for 5 min. Supernatant (20 .mu.L/lane) was loaded onto a 4-20% polyacrylamide Bio-Rad Ready-Gel (10.times.10 cm) together with a phospho-MAP kinase protein standard (New England BioLabs) and molecular weight markers. Proteins were fractionated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred by electrophoresis to a PVDF membrane (Bio-Rad). The membrane was blocked with 5% nonfat dry milk. Phosphorylated MAP kinase was labeled with a rabbit anti-phospho-MAP kinase antibody (New England New England BioLabs) and HRP-conjugated goat anti-rabbit IgG according to standard western blot procedure. The phospho-MAP kinase complex was detected by chemiluminescence using Lumiglow reagent (New England BioLabs) and Kodak X-Omat film, with exposure times ranging from 10 to 120 seconds.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6579691 B1

L5: Entry 7 of 31 File: USPT Jun 17, 2003

DOCUMENT-IDENTIFIER: US 6579691 B1
TITLE: Protein kinase NPK-110

Detailed Description Text (53):
REFERENCES Albala, J. S., Kalcheva, N., Schafit-Zagardo, B. (1993). Characterisation of the transcripts encoding 2 isoforms of human microtubule-associated protein-2 (MAP-2). Gene 136, 377-378. Anderton, B. H. (1993). Expression and processing of pathological proteins in Alzheimer's disease. Hippocampus 3, 227-237. Baas, P. W., Pienkowski, T. P., and Kosik, K. S. (1991). Processes induced by tau expression in Sf9-cells have an axon-like microtubule organisation. J. Cell Biol. 115, 1333-1344. Baumann, K., Mandelkow, E.-M., Biernat, J., Piwnica-Worms, H., Mandelkow, E.(1993). Abnormal Alzheimer-like phosphorylation of tau protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336, 417-424. Berling, B., Wille, H., Roll, B., Mandelkow, E.-M., Garner, C., Mandelkow, E.(1994). Phosphorylation of microtubule-associated proteins MAP2a, b and MAP2c at serine 136 by proline-directed kinases in vivo and in vitro. Eur. J. Cell Biol. 64, 120-130. Biernat, J., Mandelkow, E.-M., Schroter, C., Lichtenberg-Kraag, B., Steiner, B., Berling, B., Meyer, H. E., Mercken, M., Vandermeeren, A., Goedert, M., Mandelkow, E. (1992). The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11, 1593-1597. Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.-M., Mandelkow, E. (1993). Phosphorylation of serine 262 strongly reduces the binding of tau protein to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11, 153-163. Boyle, W. J., van der Geer, P. and Hunter, T. (1991). Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin layer cellulose plates. Methods Enzymol. 201, 110-149. Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V. M. Y. (1993). Abnormal tau phosphorylation at Ser(396) in Alzheimer's disease

recapitulates development and contributes to reduced microtubule binding. Neuron 10, 1089-1099. Brandt, R. and Lee, G. (1993). Functional organisation of microtubule-associated protein tau: Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. J. Biol. Chem. 268, 3414-3419. Brion, J. P., Hanger, D. P., Couck, A. M., and Anderton, B. H. (1991). A68 proteins in Alzheimers-disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities. Biochem. J. 279, 831-836. Brugg, B., and Matus, A. (1991). Phosphorylation determines the binding of microtubule-associated protein-2 (MAP2) to microtubules in living cells. J. Cell Biol. 114, 735-743. Butler, M. and Shelanski, M. L. (1986). Microheterogeneity of microtubule-associated tau-proteins is due to differences in phosphorylation. J. Neurochem. 47, 1517-1522. Butner, K. A., and Kirschner, M. W. (1991). Tau-protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 115, 717-730. Casnelli, J. E. (1991). Assay of protein kinases using peptides with basic residues for phosphocellulose binding. Meth. Enzymology 200, 115-120. Chapin, S. J. and Bulinski, J. C. (1991). Non-neuronal 210 kD Mn microtubule-associated protein (MAP4) contains a domain homologous to the microtubule-binding domains of neuronal MAP2 and tau. J. Cell Sci. 98, 27-36. Chapin, S. J. and Bulinski, J. C. (1992). Microtubule stabilisation by assembly-promoting microtubule-associated proteins: A repeat performance. Cell Mot. Cytoskel. 23, 236-243. Chen, J., Kanai, Y., Cowan, N., Hirokawa, N. (1992). Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360, 674-677. Cleveland, D. W., Hwo, S.-Y. and Kirschner, M. W. (1977). Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116, 207-225. Correas, I., Diaznido, J., and Avila, J. (1992). Microtubule associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain. J. Biol. Chem. 267, 15721-15728. Drechsel, D. N., Hyman, A. A., Cobb, M. H., and Kirschner, M. W. (1992). Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141-1154. Drewes, G., Lichtenberg-Kraag, B., Doring, F., Mandelkow, E.-M., Biernat, J., Goris, J., Doree, M. and Mandelkow, E. (1992). Mitogen-activated protein (MAP) kinase transforms tau protein into an Alzheimer like state. EMBO J. 11, 2131-2138. Drewes, G., Mandelkow, E.-M., Baumann, K., Goris, J., Merlevede, W., Mandelkow, E. (1993). Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett. 336, 425-432. Drubin, D. and Kirschner, M. (1986). Tau protein function in living cells. J. Cell Biol. 103, 2739-2746. Ennulat, D. J., Liem, R. K. H., Hashim, G. A. and Shelanski, M. L. (1989). Two separate 18-amino acid domains of tau promote the polymerisation of tubulin. J. Biol. Chem. 264 5327-5330. Geahlen, R. L., Anostario, M., Low, P. S., and Harrison, M. L. (1986). Detection of protein kinase activity in sodium dodedyl sulfate-polyacrylamide gels. Anal. Biochem. 153, 151-158. Goedert, M., Spillantini, M., Jakes, R., Rutherford, D., and Crowther, R. A. (1989). Multiple isoforms of human microtubule-associated protein-tau: Sequences and localisation in neurofibrillary tangles of Alzheimers-disease. Neuron 3, 519-526. Goedert, M., Spillantini, G., Cairns, N. J. and Crowther, R. A. (1992). Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 8, 159-168. Goedert, M. (1993). Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends in Neurosci. 16, 460-465. Gong, C. X., Singh, T. J., Grundke-Iqbal, I., Iqbal, K. (1994). Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2b (calcineurin). J. Neurochem. 62, 803-806. Goode, B. L. and Feinstein, S. C. (1994). Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J. Cell Biol. 124, 769-782. Greenberg, S. G., Davies, P., Schein, J. D., Binder, L. I. (1992). Hydrofluoric acid-treated tau-PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564-569. Grundke-Iqbal, I., Iqbal, K., Tung, Y., Quinlan, M., Wisniewski, H., Binder, L.(1986). Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83, 4913-4917. Gustke, N., Steiner, B., Mandelkow, E.-M., Biernat, J., Meyer, H. E., Goedert, M., Mandelkow, E. (1992). The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Letters 307, 199-205. Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.-M., Mandelkow, E. (1994). Domains of Tau Protein and Interactions with Microtubules. Biochemistry 33, 9511-9522. Hagestedt, T., Lichtenberg, B., Wille, H., Mandelkow, E.-M. and Mandelkow, E. (1989). Tau protein becomes long and stiff upon phosphorylation: Correlation between paracrystalline structure and degree of phosphorylation. J. Cell Biol. 109, 1643-1651. Hanger, D., Hughes, K., Woodgett, J.,

Brion, J., Anderton, B. (1992). Glycogen-synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62. Hanks, S. K., and Quinn, A. M. (1991). Protein-kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Meth. Enzymol. 200, 38-62. Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., Ihara, Y.(1992). Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 26, 17047-17054. Himmler, A., Drechsel, D., Kirschner, M. and Martin, D. (1989). Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Molec. Cell. Biol. 9, 1381-1388. Hirokawa, N. (1994). Microtubule organisation and dynamics dependent on microtubule-associated proteins. Curr. Opinion Cell Biol. 6, 74-81. Hirs, C. H. W. (1967). Modification of cysteine residues. Methods Enzymol. 11, 325-329. Inglis, J. D., Lee, M., Hill, R. E. (1993). Emk, a protein-kinase with homologs in yeast maps to mouse chromosome-19. Mamm. Genome 4, 40:1-403. Ishiguro, K., Omori, A., Sato, K., Tomizawa, K., Imahori, K., and Uchida, T. (1991). A serine threonine proline kinase-activity is included in the tau-protein kinase fraction forming a paired helical filament epitope. Neurosci. Lett. 128, 195-198. Joly, J. C., and Purich, D. L. (1990). Peptides corresponding to the 2nd repeated sequence in map-2 inhibit binding of microtubule-associated proteins to microtubules. Biochemistry 29, 8916-8920. Kanemaru, K., Takio, K., Miura, R., Titani, K., and Ihara, Y. (1992). Fetal-type phosphorylation of the tau in paired helical filaments. J. Neurochem. 58, 1667-1675. Kemp, B. E. and Pearson, R. B. (1990). Protein kinase recognition sequence motifs. TIBS 15, 342-346. Kindler, S., Schwanke, B., Schulz, B. and Garner, C. C. (1990). Complete cDNA sequence encoding rat high and low molecular weight MAP2. Nucl. Acids Res. 18, 2822. Kobayashi, S., Ishiguro, K., Omori, A., Takamatsu, M., Arioka, M., Imahori, K., Uchida, T. (1993). A cdc2-related kinase pssalre/cdk5 is homologous with the 30 kDa subunit of tau protein kinase-ii, a proline-directed protein-kinase associated with microtubule. FEBS Letters 335, 171-175. Kondo, J., Honda, T., Mori, H., Hamada, Y., Miura, R., Ogawara, M. and Ihara, Y. (1988). The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1, 827-834. Ksiezak-Reding, H., and Yen, S. H. (1991). Structural stability of paired helical filaments requires microtubule-binding domains of tau: A model for self-association. Neuron 6, 717-728. Ksiezak-Reding, H., Liu, W. K., and Yen, S. H. (1992). Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597, 209-219. Lang, E., Szendrei, G. I., Lee, V. M. Y. and Otvos, L. (1992). Immunological and conformation characterisation of a phosphorylated immunodominant epitope on the paired helical filaments found in Alzheimer's disease. Biochem. Biophys. Res. Comm. 187, 783-790. Lee, G., Neve, R. L., and Kosik, K. S. (1989). The microtubule binding domain of tau-protein. Neuron 2, 1615-1624. Lee, V. M. Y., Balin, B. J., Otvos, L., and Trojanowski, J. Q. (1991). A68--a major subunit of paired helical filaments and derivatised forms of normal tau. Science (Wash.) 251, 675-678. Lee, V. M. Y. and Trojanowski, J. Q. (1992). The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2, 653-656. Lee, G. and Rook, S. (1992). Expression of tau protein in non-neuronal cells: microtubule binding and stabilisation. J. Cell Sci. 102, 227-237. Lee, G. (1993). Non-motor microtubule-associated proteins. Curr. Opin. Cell Biol. 5, 88-94. Levin, D. E., Bishop, J. M. (1990). A putative protein-kinase gene (kin1+) is important for growth polarity in Schizosaccharomyces pombe. Proc. Natl. Acad. Sci. USA 87, 8272-8276. Levin, D. E., Hammond, C. I., Ralston, R. O., Bishop, J. M. (1987). Two yeast genes that encode unusual protein kinases. Proc. Natl. Acad. Sci. USA 84, 6035-6039. Lichtenberg-Kraag, B., Mandelkow, E.-M., Biernat, J., Steiner, B., Schroter, C., Gustke, N., Meyer, H. E., Mandelkow, E. (1992). Phosphorylation dependent interaction of neurofilament antibodies with tau protein: Epitopes, phosphorylation sites, and relationship with Alzheimer tau. Proc. Natl. Acad. Sci. U.S.A.

☐ 8. Document ID: US 6576437 B2

L5: Entry 8 of 31 File: USPT Jun 10, 2003

DOCUMENT-IDENTIFIER: US 6576437 B2
TITLE: Stimulus-inducible protein kinase complex and methods of use therefor

Detailed Description Text (55):
NF.kappa.B activation is known to occur under conditions that also stimulate MAP kinase pathways (Lee et al., Cell 88:213-22, 1997; Hirano, et al., J. Biol. Chem. 271:13234-38, 1996). Accordingly, further experiments were performed to detect proteins associated with MAP kinase and phosphatase cascades at various stages of purification of the IKK signalsome. In addition to RelA and I.kappa.B.beta., MEKK-1 and two tyrosine-phosphorylated proteins of .about.55 and .about.40 kDa copurified with I.kappa.B kinase activity (FIG. 1C). Antibodies to Rel A and I.kappa.B.beta. were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.), and antibodies to MEKK-1 were obtained from Upstate Biotechnology (Lake Placid, N.Y.). Other signaling components, including PKC.zeta., PP1 and PP2A, were detected in the same fractions as the I.kappa.B kinase in early chromatographic steps but did not copurify at later chromatographic steps (data not shown). Most interestingly, an unidentified protein of .about.50 kDa, detected by its crossreaction with an antibody to MKP-1, copurified with I.kappa.B kinase through several purification steps (FIG. 1C). This protein is unlikely to be MKP-1 itself, since the molecular weight of authentic MKP-1 is 38 kDa.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 9. Document ID: US 6551810 B1

L5: Entry 9 of 31 File: USPT Apr 22, 2003

DOCUMENT-IDENTIFIER: US 6551810 B1
TITLE: DSP-10 dual-specificity phosphatase

Detailed Description Text (37):
For example, [.sup.32 P]-radiolabeled substrate (e.g., MAP-kinase) may be used for the kinase reaction, resulting in radiolabeled, activated MAP-kinase. A DSP-10 polypeptide may then be tested for the ability to dephosphorylate an activated MAP-kinase by contacting the DSP-10 polypeptide with the MAP-kinase under suitable conditions (e.g., Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mg/mL bovine serum albumin for 10 minutes at 30.degree. C.; or as described by Zheng and Guan, J. Biol. Chem. 268:16116-16119, 1993). Dephosphorylation of the MAP-kinase may be detected using any of a variety of assays, such as a coupled kinase assay (evaluating phosphorylation of a MAP-kinase substrate using any assay generally known in the art) or directly, based on (1) the loss of radioactive phosphate groups (e.g., by gel electrophoresis, followed by autoradiography); (2) the shift in electrophoretic mobility following dephosphorylation; (3) the loss of reactivity with an antibody specific for phosphotyrosine or phosphothreonine; or (4) a phosphoamino acid analysis of the MAP-kinase. Certain assays may generally be performed as described by Ward et al., Nature

367:651-654, 1994 or Alessi et al., Oncogene 8:2015-2020, 1993. In general, contact of 500 pg-50 ng of DSP-10 polypeptide with 100 ng-100 .mu.g activated MAP-kinase should result in a detectable dephosphorylation of the MAP-kinase, typically within 20-30 minutes. Within certain embodiments, 0.01-10 units/mL (preferably about 0.1 units/mL, where a unit is an amount sufficient to dephosphorylate 1 nmol substrate per minute) DSP-10 polypeptide may be contacted with 0.1-10 .mu.M (preferably about 1 .mu.M) activated MAP-kinase to produce a detectable dephosphorylation of a MAP-kinase. Preferably, a DSP-10 polypeptide results in a dephosphorylation of a MAP-kinase or a phosphorylated substrate (such as a tyrosine- and/or serine-phosphorylated peptide) that is at least as great as the dephosphorylation observed in the presence of a comparable amount of native human DSP-10. It will be apparent that other substrates identified using a substrate trapping mutant as described herein may be substituted for the MAP-kinase within such assays.

Detailed Description Text (78):
In one aspect of the present invention, DSP-10 polypeptides may be used to identify agents that modulate DSP-10 activity. Such agents may inhibit or enhance signal transduction via a MAP-kinase cascade, leading to cell proliferation. An agent that modulates DSP-10 activity may alter expression and/or stability of DSP-10, DSP-10 protein activity and/or the ability of DSP-10 to dephosphorylate a substrate. Agents that may be screened within such assays include, but are not limited to, antibodies and antigen-binding fragments thereof, competing substrates or peptides that represent, for example, a catalytic site or a dual phosphorylation motif, antisense polynucleotides and ribozymes that interfere with transcription and/or translation of DSP-10 and other natural and synthetic molecules, for example small molecule inhibitors, that bind to and inactivate DSP-10.

☐ 10. Document ID: US 6511800 B1

L5: Entry 10 of 31 File: USPT Jan 28, 2003

DOCUMENT-IDENTIFIER: US 6511800 B1
**** See image for Certificate of Correction ****
TITLE: Methods of treating nitric oxide and cytokine mediated disorders

Detailed Description Text (403):
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. Abbas, A. K., et al., Cellular and Molecular Immunology, W. B. Saunders Co., Publisher, Philadelphia, Pa., 1991. Abbondanzo et al., Breast Cancer Res. Treat., 16:182(#151), 1990. Akamatsu, Ohno, Hirota, Kegoshima, Yodoi, Shigesada, "Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues," J. Biol. Chem. 272:14497-14500, 1997. Allred et al., Breast Cancer Res. Treat., 16:182(#149), 1990. Aruoma, O. I., et al., "The antioxidant action of N-acetyl cysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid," Free Rad. Biol. Med., 6:593-597, 1989. Bagasra, Michaels, Zheng, Bobroski, Spitsin, Fu, Tawadros, Koprowski, "Activation of the inducible form of nitric oxide

synthase in the brains of patients with multiple sclerosis," Proc. Natl. Acad. Sci., 92:12041-12045, 1995. Beasley and Brenner, "Role of nitric oxide in hemodialysis hypotension," Kidney Int., 42, Suppl., 38:S96-S100, 1992. Beckman et al. "Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide," Proc. Natl. Acad. Sci. U.S.A., 87:1620-1624, 1990. Beg, Ruben, Scheinman, Haskil, Rosen, Baldwin Jr., "I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention," Genes de Dev., 6:1899-1913, 1992. Begum and Ragolia, "cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells," J. Biol. Chem., 271:31166-31171, 1996. Berisha et al., "Nitric oxide as a mediator of oxidant lung injury due to paraquat," Proc. Natl. Acad. Sci. U.S.A., 91:744-749, 1994. Blenis, "Signal transduction via the MAP kinases: proceed at your own RSK," Proc. Natl. Acad. Sci. USA., 90:5889-5892, 1993. Bo, Dawson, Wesselingh, Mork, Choi, Kong, Hanley, Trapp, "Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains," Ann. Neurol. 36:778-786, 1994. Bonfoco, E., et al., "Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate on nitric oxide/superoxide in cortical cell cultures," Proc. Natl. Acad. Sci. USA, 92:7162-7166, 1995. Boughton-Smith et al., "Nitric oxide synthase activity in ulcerative colitis and Crohns disease," Lancet 342:338-340, 1993. Bradford, M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," Anal. Biochem., 72:248-254, 1976. Bredesen, "Neural apoptosis," Ann. Neurol., 38:839-851, 1995. Brown et al., Breast Cancer Res. Treat., 16:192(#191), 1990. Brugg, Mitchel, Agid, Ruberg, "Ceramide induces apoptosis in cultured mesencephalic neurons," J. Neurochem., 66:733-739, 1996. Buisson et al., "The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia," Br. J. Pharmacol., 106:766-767, 1992. Bull et al., J. Invest. Derm., 103:435, 1994. Busse, R., et al., "Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells," FEBS Lett., 275:87-90, 1990. Caira, Pacot, Bardot, Malki, Latruffe, "Transcriptional and post-transcriptional analysis of peroxisomal protein encoding genes from rat treated with an hypolipemic agent, ciprofibrate," Biochem. Pharmacol., 49:611-619, 1995. Cartier, N., J. Lopez, P. Moullier, F. Rocchiccioli, M. O. Rolland, P. Jorge, J. Mosser, J. L. Mandel, P. F. Bougneres, O. Danos, and P. Aubourg. "Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts," Proc. Natl. Acad. Sci. USA. 92:1674-1678, 1995. Casey, P. J., et al., "P21 ras is modified by a farnesyl isoprenoid," Proc. Natl. Acad. Sci. USA, 86:8323-8327, 1989. Castillo, Martinez-Cayuela, Zafra, Garcia-Peregrin, "Effect of phenylalanine derivatives on the main regulatory enzymes of cholesterogenesis," Mol. Cell. Biochem., 105:21-25, 1991. Chatterjee, "Neutral sphingomyelinase," Adv. LipidRes., 26:25-47, 1993. Chen, Y and Rosazza, J. P. N., "A bacterial nitric oxide synthase from a Nocardia species. Biochem Biophys Res Commun," 203:1251-1258, 1994. Chiueh et al. "Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl," Synapse 11:346-348, 1992. Contreras, M., J. Mosser, J. L. Mandel, P. Aubourg, and I. Singh. "The protein coded by the X-adrenoleukodystrophy gene is a peroxisomal integral membrane protein," FEBS Lett. 344:211-215, 1994. Contreras, M., T. K. Sengupta, F. Sheikh, P. Aubourg, and I. Singh. "Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes," Arch. Biochem. Biophys. 334:369-379, 1996. Corbett and McDaniel, "Selective inhibition of inducible nitric oxide synthase by aminoguanidine," Methods Enzymol., 268:398-408, 1996. Cornell, N. W. "Rapid fractionation of cell suspensions with the use of brominated hydrocarbons," Anal. Biochem. 102:326-331, 1980. Cross, Misko, Lin, Hickey, Trotter, Tilton, "Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice," J. Clin. Invest., 93:2684-2690, 1994. Dacrement, G., G. Cocquyt, and G. Vincent. "Measurement of very long chain fatty acids, phytanic acid and pristanic acid in plasma and cultured fibroblasts by gas chromatography," J. Inher. Metab. Dis. 18 Suppl. 1:76-83, 1995. Dawson, Dawson, London, Bredt, Snyder, "Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures," Proc. Natl. Acad. Sci USA, 88:6368-6371, 1991. Dbaio, Perry, Gamard, Platt, Poirier, Obeid, Hannun, "Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway," J. Exp. Med., 185:481490, 1997. Decrement, Cocquyt, Vincent, "Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibroblasts by gas chromatography," J. Inher. Metabl. Dis., 18(Suppl. 1):76-83, 1995. Devary, Gottleib, Lau, Karin, "Rapid and

preferential activation of the c-jun gene during the mammalian UV response," Mol. Cell. Biol., 11:2804-2811, 1991. Devlin, J. et al., "Nitric oxide generation. A predictive parameter of acute allograft rejection," Transplantation, 58:592-595, 1994. Dignam, J. D., et al., "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei," Nucleic Acids Res., 11: 1475-1489, 1983. Dobashi, Pahan, Chahal, Singh, "Modulation of endogenous antioxidant enzymes by nitric oxide in rat C6 glial cells," J. Neurochem., 68:1896-1903, 1997. Drapier, J-C., et al., "Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophages effector cells," J. Immunol., 140:2829-2838, 1988. Eberhardt et al., "Molecular cloning of the rat inducible nitric oxide synthase gene promoter," Biochem. Biophys. Res. Commun., 223:752-756, 1996. Eisieik & Leijersfam, "The inducible form of nitric oxide synthase (iNOS) in insulin-producing cells," Diabetes & Metabolism, 20:116-122, 1994. Evans et al., "Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis," Infec. Imm., 60:4133-4139, 1992. Feinstein, Galea, Cermak, Chugh, Lyandvert, Reis, "Nitric oxide synthase expression in glial cells: suppression by tyrosine kinase inhibitors," J. Neurochem., 62:811-814, 1994b. Feinstein, Galea, Roberts, Berquist, Wang, Reis, "Induction of nitric oxide synthase in rat C.sub.6 glial cells," J. Neurochem., 62:315-321, 1994a. Fenyk-Melody, Garrison, Brunnert, Weidner, Shen, Shelton, Mudgett, "Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene," J. Immunol., 160:2940-2946, 1998. Frohman, In: PCR.TM. Protocols: A Guide to Methods and Applications, Academic Press, NY, 1990. Galea, Feinstein, Reis, "Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures," Proc. Natl. Acad. Sci. USA, 89:10945-10949, 1992. Ganser, Kemer, Brown, Davisson, Kirschner, "A survey of neurological mutant mice. I. Lipid composition of myelinated tissue in known myelin mutants," Dev. Neurosci., 10:99-122, 1988. Geller, D. A., et al., "A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase: IL-1 beta induces hepatic nitric oxide synthesis," J. Immunol., 155:4890-4898, 1995. Geller, Lowenstein, Shapiro, Nussler, Di Silvio, Wang, Nakayama, Simmons, Snyder, Billiar, "Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes," Proc. Natl. Acad. Sci. USA, 90:3491-3495, 1993. Geng, Y., et al., "Tyrosine kinases are involved with the expression of inducible nitric oxide synthase in human articular chondrocytes," J. Cell. Physiol., 163:545-554, 1995. Guilian, D., and T. J. Baker. "Characterization of amoebid microglia isolated from developing mammalian brain," J. Neurosci. 6:2163-2178, 1986. Goldstein, J. L., et al., "Regulation of the mevalonate pathway," Nature, 343:425-430, 1990. Goureau et al., "Lipopolysaccharide and cytokines induce a macrophage-type of nitric oxide synthase in bovine retinal pigmented epithelial cells," Biochem. Biophys. Res. Commun., 186:854-859, 1992. Graves, L. M., K. E. Bomfeildt, E. W. Raines, B. C. Potts, S. G. Macdonald, W Ross, and E. G. Krebs. 1993. "Protein kinase A antagonizes platelet-derved growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells," Proc. Natl. Acad. Sci. USA. 90:10300-10304. Griffith, "Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine," Anal. Biochem., 106:207-212, 1980. Guilian and Baker, "Characterization of ameboid microglia isolated from developing mammalian brain," J. Neurosci., 6:2163-2178, 1986. Haga et al., "Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Res., 601:88-94, 1993. Hamid et al., "Induction of nitric oxide synthase in asthma," Lancet, 342:1510-1513, 1993. Hancock, J. F., et al., "Methylation and proteolysis are essential for efficient membrane binding of prenylated p21.sup.k-ras(B)," EMBO J., 10:641-646, 1991. Hannun and Bell, "Functions of sphingolipids and sphingolipid breakdown products in cellular regulation," Science, 243:500-507, 1989. Hannun, "Functions of ceramide in coordinating cellular responses to streiss," Science, 274:1855-1858, 1996. Hannun, "The sphingomyelin cycle and the second messenger function of ceramide," J. Biol. Chem., 269:3125-3127, 1994. Hardy, S. J., A. Ferranta, A. Poulos, B. S. Robinson, D. W. Johnson, and A. W. Murray. "Effect of exogenous fatty acids with greater than 22 carbon atoms (very long chain fatty acids) on superoxide production by human neutrophils," J. Immunol. 153:1754-1761, 1994. Hashmi, M., W. Stanley, and I. Singh. "Lignoceroyl-CoASH ligase: enzyme defect in fatty acid .beta.-oxidation system in X-linked childhood adrenoleukodystrophy," FEBS Lett. 196:247-250, 1986. Henin et al., "Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase," FASEB J., 9:541-546, 1995. Henkel, T., et al.,

"Rapid proteolysis of IkB-alpha is necessary for activation of transcription factor NF-kB," Nature, 365:182-185, 1993. Her, Lakhani, Zu, "Dual phosphorylation and autophosphorylation in mitogen-activated protein (MAP) kinase activation," Blochem. J., 296:25-31, 1993. Hibbs et al., "Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy," J. Clin. Invest., 89:867-877, 1992. Hooper, Bagsra, Marini, Zborek, Ohnishi, Kean, Champion, Sarker, Bobroski, Farber, Akaike, Maeda, Koprosky, "Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis," Proc. Natl. Acad Sci USA., 94:2528-2533, 1997. Hooper, Spitsin, Kean, Champion, Dickson, Chaudhry, Koprowski, "Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis," Proc. Natl. Acad. Sci. USA, 95:675-680, 1998. Hoshi, M., and Y. Kishimoto. "Synthesis of cerebronic acid from lignoceric acid by rat brain preparation. Some properties and distribution of the hydroxylation system," J. Biol. Chem. 248:4123-4130, 1973. Hu, S. X., et al., "Differential regulation by cytokines of human astrocyte nitric oxide production," Glia, 15:491-494, 1995. Ialenti et al., "Modulation of adjuvant arthritis by endogenous nitric oxide," Br. J. Pharmacol., 110:701-706, 1993. Issazadeh, Mustafa, Ljungdahl, Hojeberg, Dagerlind, Elde, Olsson, "Interferon-.gamma., interleukin 4 and transforming growth factor .beta. in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells," J. Neurosci. Res., 40:579-590, 1995. Jaffrey, S. R. et al., "Nitric oxide: a neural messenger," Annu. Rev. Cell Dev. Biol., 11:417-440, 1995. Jayadev, Lincardic, Hannun, "Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha," J. Biol. Chem., 269:5757-5763, 1994. Jelinek, T., et al., "Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation," Mol. Cell. Biol., 16:1027-1034, 1996. Joshi et al., "Effect of aminoguanidine on in vivo expression of cytokines and inducible nitric oxide synthase in the lungs of endotoxemic rats," Res. Commun. Mol. Pathol. Pharmacol. Mar., 91:339-346,1996. Kantey, Feinstein, Papa, Hermi, Karasik, "Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1," J. Biol. Chem., 270:23780-23784, 1995. Kaurs & Halliwell, "Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients," FEBS Lett., 350:9-12, 1994. Kharitonov et al., "Increased nitric oxide in exhaled air of asthmatic patients," Lancet, 343:133-135, 1994. Kikuchi, A., et al., "The post-translational modification of ras p21 is important for Raf-1 activation," J. Biol. Chem., 269:20054-20059, 1994. Kilbourn et al., "N.sup.G -methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide," Proc. Natl. Acad. Sci. U.S.A., 87:3629-3632, 1990. Klinkert, Kojima, Lesslauer, Rinner, Lassmann, Wekerle, "TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview," J. Neuroimmunol., 72(2)163-168, 1997. Kolb-Bachofen et al., "Epidermal keratinocyte expression of inducible nitric oxide synthase in skin lesions of psoriasis vulgaris," Lancet, 344:139 1994. Kolesnick and Golde, "The sphingomyelin pathway in tumor necrosis factor

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw Desc | Image

☐ 11. Document ID: US 6500942 B1

L5: Entry 11 of 31 File: USPT Dec 31, 2002

DOCUMENT-IDENTIFIER: US 6500942 B1

**** See image for Certificate of Correction ****

TITLE: Rin2, a novel inhibitor of Ras-mediated signaling

Detailed Description Text (75):
The activation of p38 MAP kinase activity was assayed using the p38 MAP Kinase Assay Kit (New England BioLabs). Specifically, total p38 MAP kinase was immunoprecipitated using a p38 MAP kinase antibody and incubated with GST-ATF-2 fusion protein in the presence of ATP and kinase buffer. Phosphorylation of ATF-2 was measured by Western blotting using a phospho-specific ATF-2 antibody and ECL.

☐ 12. Document ID: US 6500674 B1

L5: Entry 12 of 31 File: USPT Dec 31, 2002

DOCUMENT-IDENTIFIER: US 6500674 B1
TITLE: Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications

Detailed Description Text (41):
REFERENCES Andreadis A, Brown W, Kosik K (1992) Structure and novel exons of the human tau gene. Biochem 31:10626-10633. Bramblett G, Trojanowski J, Lee V (1992) Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau isoforms (A68 proteins). Lab Invest 66:212-222. Bramblett G, Goedert M, Jakes R, Merrick S, Trojanowski J, Lee V (1993) The abnormal phosphorylation of tau at Ser396 in Alzheimer's disease recapitulates phosphorylation during development and contributes to reduced microtubule binding. Neuron 10:1089-1099. Brion J, Couck A, Passareiro E, Flament-Durand J (1985a) Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol 17:89-96. Brion J, Passareiro J, Nunez J and Flament-Durand J (1985) Mise en evidence immunologique de la proteine tau au niveau des lesions de degenerescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol 95:229-235. Biernat J, Mandelkow M, Schoter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren M, Mandelkow E, The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J, 1992, 11:1593-1597. Bobrow M, Harris T, Shaughnessy K, Litt G (1989) Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Meth 125:279-285. Butner K, Kirschner (1991) Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 115:717-730. de Bont H, van Boom J, Liskamp R (1990a) Automatic synthesis of phosphopeptides by phosphorylation on the solid phase. Tetrahedron Letters 31:2497-2500. de Bont H, van Boom J, Liskamp R (1990b) N,N-diiopropyl-bis(4-chlorobenzyl)phosphoramidite: A versatile phosphitylating agent for the phosphorylation of hydroxy amino acids and preparation of protected phosphopeptides. Recueil des Travaux Chimiques des Pays-bas 109:27-28. Delacourte A, Flament S, Dibe E, Hublau P, Sablonniere B, Hemon B, Sherrer V, Defossez A (1990) Pathological proteins Tau64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease. Acta Neuropathol 80: 111-117. Delacourte A, Defossez A (1986) Alzheimer's disease: Tau proteins,

the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 76:173-180. Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow E-M, Biernat J, Goris J, Doree M, Mandelkow E (1992) Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 11:2131-2138. Flament S, Delacourte A, Hemon B, Defossez A (1989) Characterization of two pathological Tau protein variants in Alzheimer brain cortices. J Neurol Sci 92:133-141. Flament S, Delacourte A (1990) Tau Marker? Nature 346:6279. Flament S, Delacourte A, Mann D (1990) Phosphorylation of tau proteins: a major event during the process of neurofibrillary degeneration. A comparitive study between Alzheimer's disease and Down's syndrome. Brain Res 516:15-19. Ghanbari H, Kozuk T, Miller B, Riesing S (1990) A sandwich enzyme immunoassay for detecting and measuring Alzheimer's disease-associated proteins in human brain tissue. J Clin Laboratory Anal 4:189-192. Goedert M, Jakes R (1990) Expression of seperate isoforms of human tau protein: correlation with the tau protein in brain and effects on tubulin polymerization. EMBO J 9:4225-4230. Goedert M, Jakes R, Crowther R, Six J, Lubke U, Vandermeeren M, Cras P, Trojanowski JQ, Lee V (1993) The abnormal phosphorylation of tau protein at serine 202 in Alzheimer's disease recpitulates phosphorylation during development. Proc Natl Acad Sci (USA) 90:5066-5070. Goedert M, Wishik C, Crowther R, Walker J, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubuli-associated protein tau. Proc Natl Acad Sci (USA) 85:4051-4055. Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3:519-526. Goedert M, Spillantini M, Jakes R (1991) Localization of the Alz-50 epitope in recombinant human microtubule-associated protein tau. Neurosci Lett. 126:149-154. Goedert M, Cohen E, Jakes R, Cohen P (1992) p42 Map kinase phosphorylation sites in microtubule-associated protein tau one dephosphorylated by protein phosphatase 2A1: implications for Alzheimer's disease. FEBS Lett. 312:95-99. Greenberg S, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87:5827-5831. Greenberg S, Davies P, Schein J, Binder L (1992) Hydrofluoric acid-treated tauPHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564-569. Grundke-Iqbal I, Iqbal K, Tung Y, Quinlan M, Wisniewski H Binder L (1986) Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer's cytoskeletal pathology. Proc Natl Acad Sci (USA) 83:4913-4917. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung Y, Zaidi M, Wisniewski H (1986) Microtubule-associated protein tau. J Biol Chem 261:6084-6089. Harrington C, Mukaetova E, Hills R, Edwards P, Montejo de Garcini E, Novak M, Wischik C (1991) Measurement of distinct immunochemical presentations of tau protein in Alzheimer's disease. Proc Natl Acad Sci (USA) 88:5842-5846. Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, Ihara Y (1992) Protein sequence and mass spectrometric analyses of tau in Alzheimer's disease brain. J Biol Chem 267:17047-17054. Hsu S, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580. Iqbal K, Zaidi T, Thompson C, Merz P, Wisniewski H (1984) Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol 62:167-177. Iqbal K, Grundke-Iqbal I, Smith A, George L, Tung Y, Zaidi T (1989) Identification and localization of a Tau peptide to paired helical filaments of Alzheimer's disease. Proc Natl Acad Sci (USA) 86:5646-5650. Ishiguro K, Takamatsu M, Tomizawa K, Omori A, Takahashi M, Arioka M, Uchida T, Imahori K (1992) Tau protein kinase I converts noraml tau protein into AA68-like component of paired helical filaments. J Biol Chem 267:10897-10901. Kanai Y, Chen J, Hirokawa N (1992) Microtubule bundling by tau proteins in vivo: analysis of functional domains. EMBO J 11:3953-3961. Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y (1988) The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1:827-834. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497. Kosik K, Joachim C, Selkoe (1986) Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer's disease. Proc Natl Acad Sci (USA) 83:4044-4048. Labbe J, Cavadore J and Doree M (1991) M phase-specific cdc2 kinase: preparation from starfish oocytes and properties. Meth Enzymol 200:291-301. Laemmli U (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685. Ledesma M, Correas I, Avila J, Diaz-Nido J (1992) Implication of brain cdc2 and MAP2 kinases in the

phosphorylation of tau protein in Alzheimer's disease. FEBS Letters 308:218-224. Lee V, Balin B, Otvos L, Trojanowski J (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675-678. Lewis S, Wang D, Cowan N (1988) Microtubule-associated protein MAP2 shares a microtubule binding motif with Tau protein. Science 242:936-939. Mandelkow E-M, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede J, Mandelkow E (1992) Glycogen-synthase kinase-3 and the Alzheimer's-like state of microtubule-associated protein tau. FEBS Letters 314:315-321. Martin J, Gheuens J, Bruyland M, Cras P, Vandenberghe A, Masters C, Beyreuther K, Dom R, Ceuterick C, Lubke U, Van Heuverswijn H, De Winter G, Van Broeckhoven C (1991) Early-onset Alzheimer's disease in 2 large Belgian families. Neurology 41:62-68. McKahn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34:939-944. Mc Leod M, Stein M, and Beach D (1987) The product of the mei3+gene, expressed under control of the mating-type locus, induces meiosis and sporulation in fision yeast. EMBO J 6:729-736. Mercken M, Ph. D. thesis: De neurofibrillaire degeneratie bij de ziekte van Alzheimer: een benadering met monoklonale antistoffen. Antwerp, 1991. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Vanmechelen E, Van de Voorde A, Gheuens J (1992a) Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem 58:548-553. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, Martin JJ. Gheuens J (1992b) Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol 84:265-272. Otvos L, Elekes I, Lee V (1989) Solid phase synthesis of phosphopeptides. International Journal of Peptide and Protein Research 34:129-133. Perich J (1991) Synthesis of O-phosphoserine and O-phosphothreonine-containing peptides. Methods in Enzymology 201:225-233. Poulter L,. Barrat D, Scott C, Caputo C (1983) Localizations and immunoreactivities of phosphorylation sites on bovine and porcine tau proteins and a PHF-tau fragment. J Biol Chem 268:9636-9644. Roder H, Ingram V (1991) Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. J Neurosci 11:3325-3343. Sturgill T, Ray L, Anderson N, Erickson A (1991) Purification of activated protein kinase from epidermal growth factor treated 3T3--L1 fibroplasts. Meth Enzymol 200:342-351. Selden S, Pollard T (1983) Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. J Biol Chem 258(11):7064-71. Steiner B, Mandelkow E, Biernat J, Gustke N, Meyer H, Schmidt B, Mieskes G, Soling H, Drechsel D, Kirschner M, Goedert M, Mandelkow E (1990) Phophorylation of microtubule-associated protein tau: identification of the site for Ca.sup.2 --calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. The EMBO J 9:3539-3544. Studier F, Rosenberg A, Dunn J, Dubbendorf J (1990) Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 185:60-89. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins form polyacrylamide gels to nitrocellulose sheets : procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354. Vandenheede J, Yang S, Goris J, Merlevede W (1980) ATP.times.Mg-dependent protein phosphatase from rabbit skeletal muscle. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. J Biol Chem 25: 11768-11774. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J, Cras, P (1993) Detection of tau proteins in normal and Alzheimer's disease fluid with a sensitive sandwich enzyme linked assay J Neurochem 61:1828-1834. Vulliet R, Halloran S, Braun R, Smith A, Lee, G (1992) Proline-directed phosphorylation of human tau protein. J Biol Chem 267:22570-22574. Watanabe N, Takio K, Hasegawa M, Arai T, Titani K, Ihara Y, (1992) Tau 2: a probe for a ser conformation in the amino terminus of tau. J Neurochem 58:960-966. Wischik C, Novak M, Edwards P, Klug A, Tichelaar W, Crowther R (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85:4884-4888. Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 22:521-526. Wolozin B, Pruchnicki A, Dickson D, Davies P (1986) A neurological antigen in the brains of Alzheimer's patients. Science 232:648-650. Wood J, Mirra S, Pollock N, Binder L (1986) Neurofibrillary tangles of Alzheimer's disease share antigenic determinants with the axonal mirotubule-associated protein tau. Proc Natl Acad Sci (USA) 83:4040-4043.

☐ 13. Document ID: US 6492363 B2

L5: Entry 13 of 31 File: USPT Dec 10, 2002

DOCUMENT-IDENTIFIER: US 6492363 B2
TITLE: 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives

Detailed Description Text (77):
To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific antibody, and the resulting immunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000.times.g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 .mu.L of 1% SDS containing 1 mM NaVO.sub.4. Following alternate boiling and vortexing to denature cellular protein, 900 .mu.L RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate, and 10 mM EDTA) was added. To this mixture was added 60 .mu.L agarose beads coupled with rabbit immunoglobulin G and 60 .mu.L Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was incubated at 4.degree. C. for 15 minutes then centrifuged at 13,000.times.g for 10 minutes. The resulting supernatant was transferred to fresh tubes and incubated with 10 .mu.L of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4.degree. C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4.degree. C. The beads were pelleted by centrifugation at 13,000.times.g for 5 minutes and washed three times with 1 mL RIPA buffer. Laemmli sample buffer was added to the final bead pellet. This mixture was boiled for 5 minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1% ovalbumin and 1% bovine serum albumin in TBST (150 mM NaCl, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available antibody directed against phosphotyrosine. Antibody bound on the membrane was detected by incubation with .sup.125 I-protein A, followed by autoradiography.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 14. Document ID: US 6492157 B1

L5: Entry 14 of 31 File: USPT Dec 10, 2002

DOCUMENT-IDENTIFIER: US 6492157 B1

TITLE: DSP-9 dual-specificity phosphatase

Detailed Description Text (37):
For example, [.sup.32 P]-radiolabeled substrate (e.g., MAP-kinase) may be used for the kinase reaction, resulting in radiolabeled, activated MAP-kinase. A DSP-9 polypeptide may then be tested for the ability to dephosphorylate an activated MAP-kinase by contacting the DSP-9 polypeptide with the MAP-kinase under suitable conditions (e.g., Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mg/mL bovine serum albumin for 10 minutes at 30.degree. C.; or as described by Zheng and Guan, J. Biol. Chem. 268:16116-16119, 1993). Dephosphorylation of the MAP-kinase may be detected using any of a variety of assays, such as a coupled kinase assay (evaluating phosphorylation of a MAP-kinase substrate using any assay generally known in the art) or directly, based on (1) the loss of radioactive phosphate groups (e.g., by gel electrophoresis, followed by autoradiography); (2) the shift in electrophoretic mobility following dephosphorylation; (3) the loss of reactivity with an antibody specific for phosphotyrosine or phosphothreonine; or (4) a phosphoamino acid analysis of the MAP-kinase. Certain assays may generally be performed as described by Ward et al., Nature 367:651-654, 1994 or Alessi et al., Oncogene 8:2015-2020, 1993. In general, contact of 500 pg-50 ng of DSP-9 polypeptide with 100 ng-100 .mu.g activated MAP-kinase should result in a detectable dephosphorylation of the MAP-kinase, typically within 20-30 minutes. Within certain embodiments, 0.01-10 units/mL (preferably about 0.1 units/mL, where a unit is an amount sufficient to dephosphorylate 1 nmol substrate per minute) DSP-9 polypeptide may be contacted with 0.1-10 .mu.M (preferably about 1 .mu.M) activated MAP-kinase to produce a detectable dephosphorylation of a MAP-kinase. Preferably, a DSP-9 polypeptide results in a dephosphorylation of a MAP-kinase or a phosphorylated substrate (such as a tyrosine- and/or serine-phosphorylated peptide) that is at least as great as the dephosphorylation observed in the presence of a comparable amount of native human DSP-9. It will be apparent that other substrates identified using a substrate trapping mutant as described herein may be substituted for the MAP-kinase within such assays.

Detailed Description Text (78):
In one aspect of the present invention, DSP-9 polypeptides may be used to identify agents that modulate DSP-9 activity. Such agents may inhibit or enhance signal transduction via a MAP-kinase cascade, leading to cell proliferation. An agent that modulates DSP-9 activity may alter expression and/or stability of DSP-9, DSP-9 protein activity and/or the ability of DSP-9 to dephosphorylate a substrate. Agents that may be screened within such assays include, but are not limited to, antibodies and antigen-binding fragments thereof, competing substrates or peptides that represent, for example, a catalytic site or a dual phosphorylation motif, antisense polynucleotides and ribozymes that interfere with transcription and/or translation of DSP-9 and other natural and synthetic molecules, for example small molecule inhibitors, that bind to and inactivate DSP-9.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw Desc | Image

☐ 15. Document ID: US 6486301 B1

L5: Entry 15 of 31 File: USPT Nov 26, 2002

DOCUMENT-IDENTIFIER: US 6486301 B1

TITLE: Interleukin-20

Detailed Description Text (395):
A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6 ng/well) or 50 ul of the supernatants obtained in Example 12 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate. After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10 ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1 ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by IL-20 or a molecule induced by IL-20.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Drawi Desc | Image

---

☐ 16. Document ID: US 6399633 B1

L5: Entry 16 of 31 File: USPT Jun 4, 2002

DOCUMENT-IDENTIFIER: US 6399633 B1
TITLE: Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation

Drawing Description Text (6):
FIG. 5. Effects of flavopiridol on MAP kinase activity in HASMC. Quiescent HASMC were treated in the presence (+) or absence (-) of bFGF (10 ng/ml), thrombin (2 U/ml), PD98059 (30 .mu.mol/L) and/or flavopiridol (75 nmol/L) for 30 min. Levels of phosphorylated Erk1 (pErk1) and Erk2 (pErk2) were measured by immunoblotting with a phosphorylation-specific antibody recognizing both proteins (upper panel). MAP kinase activity was measured with an in-gel kinase assay, using myelin basic protein as a substrate (lower panel).

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Drawi Desc | Image

---

☐ 17. Document ID: US 6350856 B1

L5: Entry 17 of 31 File: USPT Feb 26, 2002

DOCUMENT-IDENTIFIER: US 6350856 B1
TITLE: Cytokine suppressive anti-inflammatory drug binding protein

Detailed Description Text (62):
It is expected that p38beta2, like other MAP kinase, will be activated by a MAP kinase kinase, hence the recombinant protein would allow the establishment of a second assay which measures the ability of p38beta 2 to be phosphorylated by putative MAP kinase kinases. In this case fractions from stimulated cell lysates (eg THP.1 cells stimulated with LPS) are incubated with p38beta2 in the presence of .gamma.-.sup.32 P-ATP, and the incorporation of .sup.32 P-label into p38beta2 measured by separation and counting. Also, tyrosine phsophorylation of p38beta2 could be detected by immunoprecipitation or immunoblot with commercially available anti-phosphotyrosine antibodies.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 18. Document ID: US 6319955 B1

L5: Entry 18 of 31 File: USPT Nov 20, 2001

DOCUMENT-IDENTIFIER: US 6319955 B1
**** See image for Certificate of Correction ****
TITLE: Use of MEK1 inhibitors as protective agents against damage due to ischemia

Drawing Description Text (6):
FIG. 5 shows that MEK inhibition blocks cell death induced by glutamate toxicity. (A) Extracellular glutamate (5 mM) induces death in HT22 cells by incubation for 10 hours. Cell viability was determined by the MTT assay; percent cell survival is presented as mean.+-.SEM (n=4). (B,C) Effects of U0126 (Promega), PD98059 (New England Biolabs) and SB203580 (Tocris) on injury in HT22 cells by incubating with glutamate (5 mM) for 9 hr (B) or 24 hr (C) was assessed by MTT assay 24 hr after addition of glutamate. Percent cell survival is presented as mean.+-.SEM (n=4). Pretreatment with SB203580 (50 .mu.M), an inhibitor of p38 MAP kinase and SAPKs/JNKs at this concentration, does not protect HT22 cells. PD98059 (50 .mu.M) and U0126 (10 .mu.M) MEK1-specific inhibitors attenuated cell injury (B, C). (D) Dose-dependent protection with U0126 in HT22 cells treated with glutamate (5 mM) for 24 hours (filled diamonds). U0126 is not toxic up to 10 .mu.M (open squares). (E) U0126 inhibits the phosphorylation of ERK1/2 in HT22 cells treated with glutamate, however does not affect total ERK1/2 protein levels. Immunoblotting was done with an antibody that specifically recognizes phosphorylated ERK1 and ERK2 (upper panel; New England Biolabs, dilution 1:1000) or with an antibody that recognizes ERK1/2 regardless of its phosphorylation state (lower panel; New England Biolabs, dilution 1:1000). (F) Effect of delayed application of U0126 on cell survival after glutamate toxicity. Ten .mu.M U0126 was added to HT22 cells at the indicated time after exposure to 5 mM glutamate, and cell survival was determined by MTT assay 24 hours after glutamate addition. Percent cell survival is presented as mean.+-.SEM (n=4). Application of U0126 was initiated up to 7 hours after glutamate completely inhibited cell death.

☐ 19. Document ID: US 6310060 B1

L5: Entry 19 of 31 File: USPT Oct 30, 2001

DOCUMENT-IDENTIFIER: US 6310060 B1
TITLE: 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors

Detailed Description Text (61):
To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific antibody, and the resulting immunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000.times.g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 .mu.L of 1% SDS containing 1 mM NaVO.sub.4. Following alternate boiling and vortexing to denature cellular protein, 900 .mu.L RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate, and 10 mM EDTA) w as added. To this mixture was added 60 .mu.L agarose beads coupled with rabbit immunoglobulin m and 60 .mu.L Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was incubated at 4.degree. C. for 15 minutes then centrifuged at 13,000.times.g for 10 minutes. The resulting supersatant was transferred to fresh tubes and incubated with 10 .mu.L of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4.degree. C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4.degree. C. The beads were pelleted by centrifugation at 13,000.times.g for 5 minutes and washed three times with 1 mL RIPA buffer. Laemmli sample buffer was added to the final bead pellet. This mixture was boiled for 5 minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1% ovalbumin and 1% bovine serum albumin in TBST (150 mM NaCl, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available a ntibody directed against phosphotyrosine. Antibody bound on the membrane was detected by incubation with .sup.125 I-protein A, followed by autoradiography.

☐ 20. Document ID: US 6300081 B1

L5: Entry 20 of 31 File: USPT Oct 9, 2001

DOCUMENT-IDENTIFIER: US 6300081 B1
TITLE: Activated ras interaction assay

Brief Summary Text (11):
A primary target of activated Ras during growth factor stimulation is Raf, which is the first component of a protein kinase cascade that leads to activation of the MAP kinases Erk1 and Erk2 (Avruch et al., "Raf Meets Ras: Completing the Framework of a Signal Transduction Pathway," Trends Biochem. Sci., 19:279-83 (1994)). The phosphorylation of transcription factors by these MAP kinases results in the expression of immediate early response genes, such as c-fos, that are required for early G1 progression. Although these signalling events occur within minutes of growth factor stimulation, microinjection of neutralizing anti-Ras antibodies in late G1 phase blocks progression of fibroblasts into S phase (Mulcahy, et al., "Requirement for Ras Proto-oncogene Function During Serum-Stimulated Growth of NIH 3T3 Cells, Nature, 313:214-43 (1985)). Furthermore, studies using combinations of cell cycle inhibitors and anti-Ras microinjection clearly demonstrate multiple points of Ras requirement in early and late G1 phase (Dobrowolski et al., "Cellular Ras Activity Is Required for Passage Through Multiple Points of the G-0-G-1 Phase in BALB-c 3T3 Cells," Molecular and Cellular Biology, 14:5441-49 (1994). These findings, together with the observations that expression of oncogenic Ras increases cyclin D1 levels and shortens G1 phase (Liu, et al., "Ras Transformation Results in an Elevated Level of Cyclin D1 and Acceleration of G1 Progression in NIH 3T3 Cells," Mol. Cell Biol., 15:3654-63 (1995); Winston et al., "Regulation of the Cell Cycle Machinery by Oncogenic Ras," Oncogene, 12:127-34 (1996)) and that Ras and cyclin D1 cooperate in cellular transformation assays (Hinds et al., "Function of a Human Cyclin Gene as an Oncogene," Proc. Natl. Sci. USA, 91:709-13 (1994); Lovec et al., "Oncogenic Activity Cyclin D1 Revealed Through Cooperation with Ha-ras; Link Between Cell Cycle Control and Malignant Transformation," Oncocene, 9:323-26 (1994)) point to an important role for Ras in regulating progression from G1 into S phase.

☐ 21. Document ID: US 6291240 B1

L5: Entry 21 of 31 File: USPT Sep 18, 2001

DOCUMENT-IDENTIFIER: US 6291240 B1
TITLE: Cells or tissues with increased protein factors and methods of making and using same

Detailed Description Text (82):
Determination of mitogen-activated protein kinase (MAP) activation in fibroblast cells exposed to various stress/environmental stimuli was carried out as follows: ERK (Extracellular Receptor-activated Kinase), SAPK/JNK (Stress-Activated Protein Kinase/Jun Kinase) and p38 were estimated in 1% triton extracts of fibroblasts that had been exposed to various environmental stimuli using commercial kits for MAP kinase activity from New England Biolabs, Beverly, Mass. The MAP kinase was immunoprecipitated using a commercially available anti-MAP kinase antibody (New England Biolabs) and the precipitate was incubated with a specific artificial fusion protein substrate: Elk-1 for ERK, c-Jun for SAPK/JNK, and ATF-2 for p38 and ATP (New England Biolabs). The products were identified on Western blots using antibodies specific for the phosphorylated form of the substrate (New England Biolabs) and visualized by enzymatic chemiluminescence using the commercially available ECL kit Phototope (New England Biolabs).

☐ 22. Document ID: US 6288089 B1

L5: Entry 22 of 31 File: USPT Sep 11, 2001

DOCUMENT-IDENTIFIER: US 6288089 B1
TITLE: Use of kinase inhibitors for treating neurodegenerative diseases

Detailed Description Text (170):
In this Example, experiments to observe p38 MAP kinase activity are described. Cultured embryonic rat mesencephalon tissue are cultured as described in Example 1. After washing with ice-cold HBSS, the cells are solubilized in 400 .mu.l of ice-cold immunoprecipitation buffer containing 10 mM Tris, pH 7.4, 1% Triton X-100, 0.5% nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium orthovanadate, and 0.2 mM phenylmethylsulfonyl fluoride. The cell lysates are centrifuged to remove insoluble material, and 200 .mu.g of the supernatant protein (400 .mu.L, total volume) are incubated with 1 .mu.g of anti-p38 antibodies for 1 hour at 4.degree. C. followed by incubation with 30 .mu.L of Protein G Plus/Protein Agarose for an additional hour. The immunocomplexes are pelleted and washed twice in immunoprecipitation buffer and then once in kinase wash buffer (50 mM .beta.-glycerophosphate, 1 mM EGTA, 20 mM MgCl.sub.2, 100 .mu.M sodium orthovanadate). The protein kinase assay is initiated by the addition of 20 .mu.L of 2.times. reaction buffer (50 mM .beta.-glycerol phosphate, 1 mM EGTA, 20 mM MgCl.sub.2, 100 .mu.M sodium orthovanadate, 0.1 mg/ml ATF-2 (N-terminal half), 50 .mu.g/ml IP20, a peptide inhibitor of cAMP dependent protein kinase, 200 .mu.M ATP, and 0.9 mCi/ml [.sup.32 P]ATP) to 20 .mu.L of immune complex. The reaction is allowed to proceed for 10 min at 30.degree. C. and then terminated by the addition of 2.times.Laemmli sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis using 12% acrylamide gels. After electrophoresis, the gels are dried and subjected to phosphoimaging (BioRad GS 100).

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 23. Document ID: US 6258579 B1

L5: Entry 23 of 31 File: USPT Jul 10, 2001

DOCUMENT-IDENTIFIER: US 6258579 B1
TITLE: Stimulus-inducible protein kinase complex and methods of use therefor

Detailed Description Text (55):
NF.kappa.B activation is known to occur under conditions that also stimulate MAP kinase pathways (Lee et al., Cell 88:213-22, 1997; Hirano, et al., J. Biol. Chem. 271:13234-38, 1996). Accordingly, further experiments were performed to detect proteins associated with MAP kinase and phosphatase cascades at various stages of purification of the IKK signalsome. In addition to RelA and I.kappa.B.beta., MEKK-1 and two tyrosine-phosphorylated proteins of .about.55 and .about.40 kDa copurified with I.kappa.B kinase activity (FIG. 1C). Antibodies to Rel A and I.kappa.B.beta. were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.), and antibodies to MEKK-1 were obtained from Upstate Biotechnology (Lake Placid, N.Y.). Other signaling components, including PKC.zeta., PP1 and PP2A, were detected in the same fractions as the I.kappa.B kinase in early chromatographic steps but did not copurify at later chromatographic steps (data not shown). Most interestingly, an unidentified protein of .about.50 kDa, detected by its crossreaction with an antibody to MKP-1, copurified with I.kappa.B kinase through several purification steps (FIG. 1C). This protein is unlikely to be MKP-1 itself, since the molecular weight of authentic MKP-1 is 38 kDa.

☐ 24. Document ID: US 6251943 B1

L5: Entry 24 of 31 File: USPT Jun 26, 2001

DOCUMENT-IDENTIFIER: US 6251943 B1
TITLE: Method of treating or preventing septic shock by administering a MEK inhibitor

Detailed Description Text (195):
To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific antibody, and the resulting inmmunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000.times.g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 .mu.L of 1% SDS containing 1 mM NaVO.sub.4. Following alternate boiling and vortexing to denature cellular protein, 900 .mu.L RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate, and 10 mM EDTA) was added. To this mixture was added 60 .mu.L agarose beads coupled with rabbit immunoglobulin G and 60 .mu.L Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was incubated at 4.degree. C. for 15 minutes then centrifuged at 13,000.times.g for 10 minutes. The resulting supernatant was transferred to fresh tubes and incubated with 10 .mu.L of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4.degree. C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4.degree. C. The beads were pelleted by centrifugation at 13,000.times.g for 5 minutes and washed three times with 1 mL RIPA buffer. Laemmli sample buffer was added to the final bead pellet. This mixture was boiled for 5 minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1% ovalbumin and 1% bovine serum albumin in TBST (150 mM NaCl, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available antibody directed against phosphotyrosine. Antibody bound on the membrane was

detected by incubation with .sup.125 I-protein A, followed by autoradiography.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 25. Document ID: US 6214795 B1

L5: Entry 25 of 31 File: USPT Apr 10, 2001

DOCUMENT-IDENTIFIER: US 6214795 B1
TITLE: Peptide compounds useful for modulating FGF receptor activity

Detailed Description Text (60):
The effect of peptide compounds on the functional activity of an FGF receptor can be evaluated in one or both of the functional assays described in this example. The first assay is a signal transduction assay, exploiting the fact that bFGF binding to FGFR initiates a phosphorylation cascade that includes the phosphorylation of MAP kinase (MAP-K). Accordingly, the ability of a test compound to modulate bFGF-induced phosphorylation of MAP-K is examined. NIH 3T3 cells are synchronized to quiescence by growing in medium containing 0.5% fetal bovine serum (FBS) for 2 days. The cells are then shifted into fresh 0.5% FBS-containing medium for 2 hours to reduce the basal level of MAP-K phosphorylation before the experiment. Test peptide compounds are dissolved in fresh dimethyl sulfoxide (DMSO) to 100 mg/ml and series dilutions are made in DMSO. Peptides at various dilutions are added to medium containing bFGF (1 or 10 .mu.M). Phosphorylation of MAP-K in the 3T3 cells is initiated by incubating the cells with the bFGF-containing medium in the presence or absence of test peptide for 15 minutes at 37.degree. C. The phosphorylation is stopped by washing with cells with PBS and lysing the cells with sodium dodecyl sulfide (SDS)-containing buffer. Cell lysates are separated on 12% SDS polyacrylamide gels and the proteins are transferred onto PVDF membranes. Membrane-bound cellular proteins are probed with a rabbit anti-phosphoMAP-K antibodies, followed by a goat anti-rabbit secondary antibody, labeled with horse radish peroxidase. The blots are then detected by the enhanced chemiluminescence (ECL) method.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 26. Document ID: US 6166289 A

L5: Entry 26 of 31 File: USPT Dec 26, 2000

DOCUMENT-IDENTIFIER: US 6166289 A
TITLE: IRAK modified transgenic animals

Detailed Description Text (60):
In vitro kinase assay. After stimulation, cells were lysed in NP40 lysis buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 1% Nonidet P 40, 1 mM Na.sub.3 VO.sub.4) containing EDTA-free complete protease inhibitor cocktail (Boehringer Mannheim Corp., Indianapolis, Ind.), centrifuged at 16,000.times.g for 10 minutes, and precleared twice with 50 1 of GammaBind G Sepharose slurry (Pharmacia Biotech, Inc., Piscataway, N.J.). MAP kinases were immunoprecipitated with 50 1 GammaBind G Sepharose slurry and 2 .mu.g polyclonal rabbit antibody, specific for the 20 C-terminal residues of p38 .alpha. or the 17 C-terminal residues of JNK1 (Santa Cruz Biotechnology, Santa Cruz, Calif.). Immunoprecipitates were washed twice with NP40 lysis buffer and twice with kinase reaction buffer (25 mM HEPES pH 7.5, 10 mM MgCl.sub.2, 10 mM MnCl.sub.2, 20 mM .beta.-glycerophosphate, 1.times. EDTA-free complete protease inhibitor cocktail). Kinase reactions were performed for 20 minutes at 30.degree. C. in kinase reaction buffer containing 50 .mu.M ATP and 5 .mu.Ci .gamma.-.sup.32 P-ATP (3000 Ci/mmol, Amersham Corp., Arlington Heights, Ill.) with 0.5 .mu.g GST-MAPKAPK2 (Upstate Biotechnology, Lake Placid, N.Y.) as p38 substrate or 2 .mu.g GST-c-JUN (BioMol, King of Prussia, Pa.) as JNK-1 substrate. Samples were boiled in SDS sample buffer, electrophoresed in 10% Tris-Glycine polyacrylamide gels and transferred to PVDF membranes (Novex, San Diego, Calif.). Bands were quantified on a Storm 840 PhosphorImager System (Molecular Dynamics Inc., Sunnyvale, Calif.). Membranes were stained for p38 and JNK1 protein using the p38 and JNK1 antibodies described above and the Vistra ECF Western blotting system (Amersham).

☐ 27. Document ID: US 6136596 A

L5: Entry 27 of 31 File: USPT Oct 24, 2000

DOCUMENT-IDENTIFIER: US 6136596 A
TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Detailed Description Text (145):
To examine the specificity of MKK7 in vivo, cotransfection assays were performed. CHO cells were maintained in Dulbecco's modified Eagle's medium supplemented with fetal calf serum (5%; Gibco-BRL). The cells were transfected with the lipofectamine reagent according to the manufacturer's recommendations (Gibco-BRL) Derijard (1994) supra). Cells were co-transfected with vectors encoding epitope-tagged JNK1 together with an empty expression vector (control) or an expression vector encoding MKK4 or MKK7. The epitope tag was derived from the hemagglutinin protein (HA) of the influenza virus. JNK1 was isolated by immunoprecipitation of cell lysates. The cells were solubilized with lysis buffer (20 mM Tris (pH 7.4), 1% TRITON X-1000, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM .gamma.-glycerophosphate, 1 mM Na orthovanadate, 2 mM pyrophosphate, 1 mM PMSF, 10 .mu.g/ml leupeptin) and centrifuged at 100,000.times.g for 15 minutes at 4.degree. C. The epitope-tagged protein kinases were immunoprecipitated by incubation for 3 hours at 4.degree. C. with an anti-HA monoclonal antibody bound to protein-G Sepharose (Pharmacia-LKB Biotechnology Inc.). The immunoprecipitates were washed three times with lysis buffer (Gupta et al. (1995) Science 267:389-393). Protein kinase activity was measured in the immunecomplex with [.gamma.-.sup.32 P]ATP and

c-Jun as substrates. The product of the phosphorylation reaction was visualized after SDS-PAGE by autoradiography. The ERK2 and p38 MAP kinases were not activated by co-expressed MKK7. Control experiments demonstrated that the ERK2 and p38 MAP kinases were activated by their respective cognate MAP kinase kinases, MKK1 and MKK6. In contrast, MKK7 did activate JNK1. Interestingly, the activation of JNK1 by co-expressed MKK7 was greater than that caused by the previously described JNK activator MKK4. Together, these data establish that MKK7 can function as a specific activator of JNK in cultured cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 28. Document ID: US 6001580 A

L5: Entry 28 of 31 File: USPT Dec 14, 1999

DOCUMENT-IDENTIFIER: US 6001580 A
TITLE: Method for assaying ERK2 map kinase

Detailed Description Text (274):
The monoclonal antibody HE113 specific for human MAP kinase ERK1, prepared in Example 2, and the polyclonal antibody (anti-peptide-3 antibody) specifically binding to MAP kinase ERK1, prepared in Example 9, were respectively diluted to 20 .mu.g/ml with 10 mM NaHCO.sub.3 buffer (pH 8.0) and added to a 96-well EIA plate (Corning, No. 430480), 100 .mu.l per well. Each assay plate was then allowed to sit at 4.degree. C. overnight so as to let the antibody immobilized to the solid phase. After the wells were rinsed twice with PBS (8.1 mM disodium phosphate, 1.5 mM potassium phosphate, 27 mM potassium chloride, 137 mM NaCl, pH 7.2), 300 .mu.l/well of PBS containing 25% of Block Ace (Snow Brand Milk Products Co.) was added and the plate was stored cold until needed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 29. Document ID: US 5731343 A

L5: Entry 29 of 31 File: USPT Mar 24, 1998

DOCUMENT-IDENTIFIER: US 5731343 A
TITLE: Method of use of radicicol for treatment of immunopathological disorders

Detailed Description Text (65):
The time course of protein tyrosine phosphorylation in LPS-stimulated macrophages showed that the maximum

phosphorylation occurred within 1 hour whether cells were treated with radicicol or not (FIG. 2A). Both MAPK- 1 (42 KD) and MAPK-2 (44 KD) were detected in cell lysates derived from the time course study as determined by Western blot analysis using polyclonal anti-rat MAP kinase antibodies recognizing both MAPK-1 and MAPK-2 (FIG. 2B). However, these MAP kinases did not appear to be tyrosine phosphorylated significantly at the incubation conditions used in our studies (FIG. 2A). Tyrosine phosphorylated MAPKs were not detected by the anti-phosphotyrosine immunoblot procedure described herein. When 2% BSA, instead of 3% dry milk was utilized in the blocking buffer, tyrosine phosphorylated MAPKs were detectable as shown in FIG. 2D. FIG. 2D shows the inhibition of tyrosine phosphorylation of mitogen activated protein kinases by radicicol in macrophage cell line (RAW 264.7, ATCC). Cells were pretreated with the indicated concentrations of radicicol for four hours, and then stimulated with LPS (1 .mu.g/ml). Solubilized proteins were analyzed by antiphosphotyrosine immunoblotting as described in FIG. 2A. Tyrosine phosphorylated MAPK bands were identified using polyclonal antibodies recognizing both MAPK-1 and MAPK-2, and polyclonal antibodies for p38. p38 is recently cloned isoform of MAPK (Han, et al., Science, 265:808, 1994).

☐ 30. Document ID: US 5723300 A

L5: Entry 30 of 31 File: USPT Mar 3, 1998

DOCUMENT-IDENTIFIER: US 5723300 A
TITLE: Nuclear localized transcription factor kinase and diagnostic assays related thereto

Detailed Description Text (12):
Consistent with a large body of work on "switch kinases" and nuclear phosphorylation (Ahn and Krebs, 1990; Pelech et al., 1987; 1990) that has failed to detect phosphotyrosine phosphorylation in the nucleus, the 90 kD species contained no phosphotyrosine, and phosphorylated its myelin basic protein substrate only on serine. Myelin basic protein is used frequently as an in vitro substrate for MAP kinases, and its suitability here suggested that the 90 kD kinase might share some structural or functional similarities with the members of the MAP kinase family or with the RSK family, which is immunologically related to the MAP kinases. However, the 90 kD kinase did not phosphorylate a range of substrates, including peptide substrates for S6 kinase, MAP kinase, casein kinase II, glycogen synthase kinase III, protein kinase C, calcium-calmodulin-dependent protein kinase, or Raytide (a general substrate for tyrosine kinases). It did phosphorylate peptide substrates for smooth muscle myosin light chain kinase and for protein kinase A and was active in the absence of cofactors. These substrate peptides have at least two hydrophobic, basic amino acids that are positioned two residues toward the N-terminus from a phosphorylatable serine (Kemp and Pearson, 1990). Amino acid sequence analysis of the phosphorylation site and site-directed mutagenesis will provide more information about the substrate requirements of the kinase. The nuclear localization of the enzyme and its lack of immunoreactivity with rabbit polyclonal antibodies to protein kinase C, RSK or MAP kinases indicated that the 90 kD kinase was unlike other previously characterized kinases.

Detailed Description Text (22):
Dextran sulfate (average molecular weight 500,000), insulin, glucagon, acidic fibroblast growth factor,

reactive green-19 and Cibacron Blue 3GA (Type 3000) agarose were from Sigma. Sodium orthovanadate, Tris, trichloroacetic acid, MgCl.sub.2 and NaOH were from Fisher. Disodium ATP and NP-40 were from Pharmacia LKB. Guanidine hydrochloride was from Fluka. Phytohemagglutinin-M, phorbol 12-myristate 13-acetate, calcium ionophore A23187, human interleukin-2, (7.beta.-deacetyl-7.beta.-[-N methylpiperazino]-buytyrl)-forskolin dihydrochloride and rat brain protein kinase C were from Calbiochem. Wheat germ extract and rabbit reticulocyte extract systems for in vitro translation were from Promega. Raytide and recombinant p43.sup.v-abl were from Oncognene science (Uniondale, N.Y.). In vitro phosphorylation substrates were from Peninsula Laboratories (Belmont, Calif.). [.alpha.- and .gamma.-.sup.32 P]ATP were from New England Nuclear. Nitrocellulose membranes were from Micron Separations (Westboro, Mass.) and polyvinyl difluoride membranes (PVDF) were from Millipore. Recombinant protein A-agarose was from Repligen (Cambridge, Mass.). Phosphocellulose resin (P-11) was from Whatman. Polyacrylamide monomer, bisacrylamide and ammonium persulfate were from National Diagnostics (Manville, N.J.). Cell culture media, calf serum, monoclonal antibody Mab 1.9 against rat brain protein kinase C and TEMED were from GIBCO-BRL. Fetal bovine serum for Jurkat cell culture was from Whittaker Bioproducts (Walkersville, Md.). Cell lines (HeLa, ATCC CCL 2; A431, ATCC CRL 1555; Jurkat, ATCC TIB 152; HUT78, ATCC TIB 161; Mvl Leu, ATCC CCL64; CHO DUKX B1, ATCC CRL 9010; CV-1, ATCC CCL70; and COS-7, ATCC CRL 1651) were obtained from ATCC and cultured as advised. Jurkat clone E6-1 (Weiss et al., 1984) and HUT78 (Gazdar et al., 1980) were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. 3T3-L1 fibroblasts (ATCC CL 173) were the kind gift of Michael P. Czech, University of Massachusetts Medical Center, and were differentiated according to Rubin et al. (1978). An Epstein-Barr virus-transformed human B-cell line (32D clone 13) (FitzGerald et al., 1991) was obtained from Joel Greenberger, University of Massachusetts Medical Center. Human peripheral blood lymphocytes from normal, healthy volunteers, were the kind gift of John Sullivan University of Massachusetts Medical Center. Rabbit polyclonal antisera to purified GST fusion proteins were prepared by Berkeley Antibody Company (Richmond, Calif.). Platelet-derived growth factor was the kind gift of Roger J. Davis, University of Massachusetts Medical Center. Rabbit anti-rat MAP kinase (erk-1 C-terminal 333-367 amino acids) polyclonal antibody was from Upstate Biotechnology (Lake Placid, N.Y.) and anti-RSK rabbit antibody was the kind gift of John Blenis, Harvard Medical School. HeLa nuclear extract was prepared with 1 mM sodium vanadate and 50 mM .beta.-glycerophosphate after the method of Dignam et al. (1983). All other reagents were from Sigma.

☐ 31. Document ID: US 5525625 A

L5: Entry 31 of 31 File: USPT Jun 11, 1996

DOCUMENT-IDENTIFIER: US 5525625 A
TITLE: 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders

Detailed Description Text (26):
To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific antibody, and the resulting immunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with

compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000.times.g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 .mu.L of 1% SDS containing 1 mM NaVO.sub.4. Following alternate boiling and vortexing to denature cellular protein, 900 .mu.L RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate, and 10 mM EDTA) was added. To this mixture was added 60 .mu.L agarose beads coupled with rabbit immunoglobulin G and 60 .mu.L Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was incubated at 4.degree. C. for 15 minutes then centrifuged at 13,000.times.g for 10 minutes. The resulting supernatant was transferred to fresh tubes and incubated with 10 .mu.L of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4.degree. C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4.degree. C. The beads were pelleted by centrifugation at 13,000.times.g for 5 minutes and washed 3 times with 1 mL RIPA buffer. Laemmli sample buffer was added to the final bead pellet. This mixture was boiled for 5 minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1% ovalbumin and 1% bovine serum albumin in TBST (150 mM NaCl, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available antibody directed against phosphotyrosine. Antibody bound on the membrane was detected by incubation with 125I-protein A, followed by autoradiography.

Terms	Documents
l4 same (monoclonal or antibody or antibodies or antisera or antiserum or mono-clonal or moab or mab or scfv or antipeptide or antisubstrate)	31